EFFECT OF HOSPITALIZATION ON THE INTEGRITY OF THE MEDICATION REGIMEN IN PATIENTS WITH DIABETES MELLITUS by Alcusky, Matthew J.
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2014 
EFFECT OF HOSPITALIZATION ON THE INTEGRITY OF THE 
MEDICATION REGIMEN IN PATIENTS WITH DIABETES MELLITUS 
Matthew J. Alcusky 
University of Rhode Island, matthew_alcusky@my.uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Alcusky, Matthew J., "EFFECT OF HOSPITALIZATION ON THE INTEGRITY OF THE MEDICATION REGIMEN 
IN PATIENTS WITH DIABETES MELLITUS" (2014). Open Access Master's Theses. Paper 311. 
https://digitalcommons.uri.edu/theses/311 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
EFFECT OF HOSPITALIZATION ON THE INTEGRITY OF THE 
MEDICATION REGIMEN IN PATIENTS WITH  
DIABETES MELLITUS 
BY 
MATTHEW J ALCUSKY 
 
 
 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
IN 
PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2014 
  
 
MASTER OF SCIENCE THESIS 
 
OF 
 
MATTHEW ALCUSKY 
 
 
 
 
 
 
 
 
 
 
APPROVED:  
 
Thesis Committee: 
 
Major Professor Stephen Kogut 
 
   Brian Quilliam 
 
   Mark Robbins 
 
       
      Nasser H. Zawia 
  DEAN OF THE GRADUATE SCHOOL 
 
 
 
 
 
 
 
UNIVERSITY OF RHODE ISLAND 
2014 
  
ABSTRACT 
Medication errors are common within the United States health system. Preventable medication 
errors are often the result of ineffective processes that contribute to the occurrence of adverse drug 
events. Care transitions, movement between settings or levels of care, present a particularly vulnerable 
time for patients. Errors are frequently introduced into a patient's medication regimen during transitions 
of care, including the inappropriate discontinuation or duplication of medications. Inappropriate 
discontinuation (non-persistence) of evidence based therapies for chronic diseases places patients at an 
increased risk for adverse health outcomes. Previous investigations have indicated that care transitions 
due to hospitalization have been associated with increased rates of non-persistence, and that non-
persistent patients were at an increased risk for poor health outcomes.  
We conducted a matched retrospective cohort study of patients enrolled with the commercial 
health insurer Blue Cross Blue Shield of Rhode Island. Patients included in the study were adults at 
least 18 years of age with diagnosed diabetes confirmed by outpatient medication use and a diagnosis 
code. We evaluated the disruptive impact of hospitalization on the medication regimen by comparing 
the odds of persistence with evidence based therapies between hospitalized and non-hospitalized 
patients. Persistence was assessed with two medication classes: angiotensin converting enzyme (ACE) 
inhibitors/angiotensin II receptor blockers (ARBs) and lipid lowering drugs (LLD). We classified 
patients with an eligible hospitalization as exposed, and matched unexposed non-hospitalized patients to 
the exposed cohort on the variables age, gender, Charlson comorbidity score and enrollment period. The 
primary outcomes of persistence and treatment duplication were assessed during the 60 day period 
following the hospitalized patient's discharge date. Differences in baseline characteristics and the 
bivariate odds of persistence were assessed between groups for the primary risk factor hospitalization as 
well as patient demographic and health related variables. We constructed multivariable logistic 
regression models to measure the effect of hospitalization on persistence with medications from each 
class while controlling for potential confounders and assessing for interaction terms. 
 A total of 201 exposed and 199 unexposed ACE inhibitor/ARB users and 202 exposed and 199 
unexposed LLD users were evaluated for persistence. After adjusting for potential confounders and an 
interaction term between hospitalization and cardiovascular disease, hospitalization was found to be a 
  
significant risk factor for non-persistence in patients using ACE inhibitors/ARBs [(Beta coefficient-
0.931 [P = 0.0283]). Patients that were hospitalized and had cardiovascular disease had an increased 
odds of persistence relative to patients that were not hospitalized and had cardiovascular disease (Odds 
Ratio (OR): 2.052 [95% CI 0.384-10.972)]. Patients that were hospitalized and did not have 
cardiovascular disease were significantly less likely to persist compared with patients that were not 
hospitalized and did not have cardiovascular disease (OR: 0.394 [95% CI 0.171-0.906]). The odds of 
persistence with LLD therapy did not differ between hospitalized patients and non-hospitalized patients 
(OR: 0.961 [95% CI 0.469-1.972]). The duration of prescription supply for study medication was found 
to be a confounder of the exposure and outcome relationship for both medication classes. Therapeutic 
duplication occurred infrequently with both medication classes regardless of exposure status and the 
low frequencies of duplication observed precluded logistic regression analysis.  
 Our results implicate hospitalization as a risk factor for non-persistence with medications 
treating chronic diseases in commercially insured patients with diabetes. Interventions such as 
medication reconciliation that strive to improve communication during transitions of care and prevent 
the introduction of errors into the medication regimen should continue to be implemented and 
evaluated. 
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CHAPTER 1 
 
INTRODUCTION 
 
 The conclusions heralded by The Quality of Health Care in America Committee of the Institute 
of Medicine in their first report  "To Err is Human: Building a Safer Health System" called for a 
system-wide quest for improvement in the quality of healthcare in the United States.1 In the report, the 
committee discerned that the majority of medical errors occur as a result of ineffective systems, 
processes, and conditions that lead individuals to make mistakes or fail to prevent them. In 2006, a 
successive report "Preventing Medication Errors" evaluated the safe, effective, and appropriate use of 
medications throughout a multitude of health care settings.2 The committee estimates that on average a 
hospitalized patient is subject to at least one medication error per day, and that at least a quarter of all 
medication-related injuries are preventable. The financial burden of preventable adverse drug events 
(ADEs) on the United States health care system is substantial. A conservative estimate of $3.5 billion 
(2006 dollars) is spent annually due to in-hospital preventable ADEs.2 A care transition is the process of 
shifting responsibility associated with a patient's movement between settings or level of care.3  
Approximately half of all hospital related medication errors may be attributed to inefficient 
communications at transitions of care.4,5  
 Transitions of care jeopardize the continued accuracy of a patient's medication regimen.6-10 
Hospitalization places patients at risk for unintentional discontinuation of evidence based therapies for 
treatment or prevention of chronic diseases.6,8 Patients undergoing an additional transition to the 
intensive care unit (ICU) are at a greater risk for discontinuity in chronic medication use.6-7  The 
occurrence of unintended medication discrepancies at the time of hospital admission has been estimated 
to occur in greater than half of patients.9,10 A prospective study by Cornish and colleagues assessed the 
accuracy of medication histories for all patients documented to be using at least 4 medications that were 
admitted from the community to a large teaching hospital in Toronto, Canada.9  The original medication 
history was obtained in the emergency department by either a nurse, physician, or medical 
resident/student. After admission, a pharmacist, pharmacy student or medical student obtained a 
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thorough medication history which was then compared with the original history. Discrepancies were 
reviewed with the admitting medical team to appropriately classify intentional and unintentional 
changes. Of 150 patients included in the study, 81 patients were found to have at least one discrepancy 
(53.6%; 95% CI 45.7%-61.6%). A total of 140 discrepancies were identified, yielding a rate of 0.93 
discrepancies per patient. Of the 140 discrepancies, 8 (5.7%) were classified as severe. A similar study 
by Gleason et al compared pharmacist obtained medication histories after admission to histories 
obtained by nursing and physician staff prior to admission.10 The proportion of patients with at least one 
medication discrepancy was greater in this study (69% ; 1.2 discrepancies/patient [SD: 1.5]), but 
discrepancies were not confirmed to be unintentional as in the study by Cornish et al.9,10   
 Inappropriate alteration of the medication regimen upon admission and discharge from the 
hospital is associated with adverse drug events and poor health outcomes.7,8 Boockvar et al examined 
the impact of care transitions on medication use in patients admitted to 2 academic hospitals from 4 
different nursing homes.8 Nursing home and hospital medical records were compared for 87 patients 
(122 admissions) and reviewed by 2 physicians to identify ADEs attributable to medication changes 
during transitions of care. A mean of 3.1 medications were altered upon transition from the nursing 
home to the hospital, which was greater than the 1.4 that were altered upon discharge back to the 
nursing home (P<0.001). Of 71 bidirectional transfers reviewed, ADEs attributable to medication 
changes occurred during 14 (20%) of these transfers and 7 (50%) of these medication changes were 
therapy discontinuations. These results suggest that patients are at risk of adverse health outcomes due 
to inappropriate medication discontinuity following transitions of care between institutions.  
 Patients admitted to a hospital have been demonstrated to incur higher rates of unintended 
discontinuations of medications treating chronic diseases as compared to non-hospitalized patients.6 
One population based cohort study evaluated the risk of unintentional discontinuation in patients 
undergoing 1 or more transitions of care. Patients were required to be continuous users for at least 1 
year of at least 1 medication from 5 medication classes: statins, antiplatelets/anticoagulants, 
levothyroxine, respiratory inhalers, and gastric acid suppressants. Compared with non-hospitalized 
patients the odds of unintentional discontinuation were increased in hospitalized patients without an 
ICU stay [(statins: OR 1.33; 95% CI 1.29-1.37), (antiplatelets/anticoagulants: OR 1.86; 95% CI 1.77-
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1.97), (levothyroxine: OR 1.18; 95% CI 1.14-1.23), (respiratory inhalers: OR 1.50; 95% CI 1.15-1.97), 
and (gastric acid suppressants: OR 1.50; 95% CI 1.43-1.56)] and increased further in hospitalized 
patients with an ICU stay [(statins: OR 1.48; 95% CI 1.39-1.57), (antiplatelets/anticoagulants: OR 2.31; 
95% CI 2.07-2.57), (levothyroxine: OR 1.51; 95% CI 1.38-1.66), (respiratory inhalers: OR 1.84; 95% 
CI 1.10-3.08), and (gastric acid suppressants: OR 1.87; 95% CI 1.71-2.05)]. These results demonstrate 
the disruptive impact one or more hospitalization related transitions of care may have on appropriate 
medication use in elderly patients.6   
National and International Focus on Medication Management During Care Transitions 
 The Joint Commission is an independent non-profit organization responsible for the 
accreditation and certification of health care organizations and programs in the United States. The Joint 
Commission's 2014 Hospital National Patient Safety Goal 03.06.01 specifies the maintenance and 
communication of accurate patient medication information.11 Performance elements for this goal 
emphasize the performance of comprehensive medication reconciliation procedures.11 The Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 included legislation that provided 
reimbursement under the newly created Medicare Part D for medication therapy management 
programs.12  A year later eleven national pharmacy professional organizations collaborated to provide a 
widely applicable and reimbursable definition of medication therapy management.13 
 Medication reconciliation, a primary component of medication therapy management, was later 
defined by an expert panel representing the American Pharmacists Association and the American 
Society of Health System Pharmacists in 2007.14 An abbreviated version of the joint definition states 
that medication reconciliation is the comprehensive evaluation of a patient's medication regimen during 
any change in therapy in an effort to avoid errors or interactions, as well as to observe compliance and 
adherence patterns. A comparison of existing and previous regimens should occur at every transition in 
care during which the regimen is modified.14 The use of pharmacists or other qualified healthcare 
professionals for medication reconciliation purposes during care transitions presents the potential for 
limiting medication errors and improving health outcomes.15-26  
 The World Health Organization (WHO) introduced the High 5's project in 2006 as an 
international initiative responsible for the implementation and evaluation of five standard operating 
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procedures (SOP) for the improvement of five areas of patient safety.27 An SOP for medication 
reconciliation entitled, " Medication Accuracy at Transitions in Care: SOP for Medication 
Reconciliation" was developed in Canada and is in the process of being implemented and evaluated in 
the Netherlands. Results reported in 2013 from the use of the SOP in 12 Dutch hospitals indicated a 
reduction in the proportion of elderly patients with at least one unintentional medication discrepancy 
upon admission from the emergency department.28 An intervention consisting of a medication history 
obtained by a pharmacy technician was associated with a reduced odds of at least one unintentional 
medication discrepancy [OR 0.29; 95% CI = 0.23-0.37] compared with usual care involving a nurse or 
physician obtained medication history.28 Complete results and disclosure of the SOP is planned for 
2015.29 
Adherence and Persistence 
 The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
Medication Compliance and Persistence Work Group defines compliance (synonym: adherence) as "the 
extent to which a patient acts in accordance with the prescribed interval and dose of a dosing 
regimen".30 The ISPOR Work Group defines persistence as "the duration of time from initiation to 
discontinuation of therapy". Persistence analyses must also include a pre-specified limit on the number 
of days allowed between refills before a patient is identified as non-persistent.30 Poor adherence to 
evidence based therapy has been frequently documented in outpatient populations.31-32 Non-persistence 
and sub-optimal adherence prevents the full therapeutic benefit of a drug from being realized and is a 
cause of preventable adverse health outcomes including mortality.33-36 Inappropriate medication taking 
behavior increases resource utilization and the risk of mortality, leading to parallel increases in 
economic costs and burdens on the health care system.2, 37-38 
Lipid Lowering and Antihypertensive Therapy in Patients with Diabetes 
 The prevalence of diagnosed diabetes mellitus has increased steadily from an age adjusted 
2.8% of the United States non-institutionalized population in 1980 to 6.4% in 2011.39 Persons with 
diabetes mellitus require appropriate lifestyle and medication interventions to mitigate an elevated risk 
of microvascular and macrovascular complications.40 Management of dyslipidemia using statin therapy 
is recommended regardless of baseline lipid levels in patients with cardiovascular disease (CVD) or in 
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those older than 40 years of age without CVD but that have at least one other CVD risk factor 
identified.41 Statin therapy is also recommended in patients that are younger than 40 years of age having 
multiple CVD risk factors or having a low density lipoprotein (LDL) cholesterol level of greater than 
100 mg/dL.41 The risk of major vascular events and all cause mortality is reduced in patients with 
diabetes using statin therapy for either primary or secondary prevention.42-44 In a meta analysis of  over 
18,000 patients with diabetes from 14 randomized controlled trials,  statin therapy was associated with a 
9% reduction in all-cause mortality and a 13% proportional reduction in vascular mortality for each 
millimole per liter reduction in low density lipoprotein (LDL) cholesterol.43 
 Inhibitors of the renin-angiotensin system (RAS) are preferred as initial therapy for 
hypertension in patients with diabetes due to associated reductions in the occurrence of microvascular 
and macrovascular outcomes.40 The HOPE study evaluated the use of the ACE inhibitor ramipril 
compared with placebo in 3,577 patients with diabetes.45 Patients were at least 55 years of age and had a 
history of a prior cardiovascular event or at least one current cardiovascular disease risk factor. The 
study was stopped before completion due to pronounced beneficial effects in patients receiving 
ramipril. The combined primary outcome of myocardial infarction, stroke, or cardiovascular death was 
reduced by 25% (95% CI: 12-36; P=0.0004), total mortality was reduced by 24% (95% CI: 8-37%) and 
nephropathy was also reduced by 24% (95% CI: 3-40%; P=0.027).45  The 2014 Standards of Diabetes 
Care recommend that patients with diabetes and a confirmed blood pressure greater than 140/80 mmHg 
have prompt initiation and titration of pharmacological antihypertensive therapy. Pharmacological 
therapy should include either an angiotensin-enzyme (ACE) inhibitor or an angiotensin receptor blocker 
(ARB), substituting one class for the other if the first is not tolerated.40  
Purpose and Hypothesis 
 The purpose of this study was to investigate the potential disruptive impact that hospitalization 
may have on medication persistence with critical medication classes used in patients that have diabetes. 
In patients with confirmed use of at least one of two classes of these evidence based medications, we 
determined if the prescriptions were renewed in the 60 day period after discharge. Furthermore, we 
compared the medication discontinuation rate of hospitalized patients to that of matched patients that 
were not hospitalized. Additionally, we measured the rate of treatment duplication (multiple 
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prescriptions from the same medication class) between hospitalized and non-hospitalized patients. The 
effect of time to follow up with a primary care physician on persistence was also examined among 
patients that were hospitalized.   
 We expected hospitalization to affect a  patient's medication regimen and medication taking 
behavior due to multiple system related factors. Upon arrival to the hospital, a medication history is 
obtained by emergency room staff. The completeness and accuracy of medication histories obtained 
prior to or during the admission process are likely to vary depending upon systemic factors including 
hospital policies, procedures and staffing models. During the course of a hospitalization, medications 
treating chronic diseases are often suspended and new medications are added in the course of managing 
the acute inpatient episode. Substitution of hospital formulary medications will also occur for non-
formulary drugs that a patient uses at home. As a patient is prepared for discharge, new medications 
added during the hospitalization may be continued and chronic medications may be resumed depending 
upon the patient's condition. Hospital formulary drugs should be changed back to the patient's original 
medication used prior to admission. Effective communication between hospital practitioners, the patient 
and/or caregiver, and outpatient practitioners is necessary to reduce the risk for introduction of errors 
into the medication regimen. 
 A patient's medication taking behavior, encompassing adherence and persistence with 
prescribed therapies, is expected to be impacted by a hospitalization. The Necessity Concerns 
Framework proposes that patient perceptions of their own need for treatment and the potential for 
adverse consequences related to treatment are the main categories of beliefs that influence patient 
adherence.46 Application of this conceptual framework in research studies has shown that adherence 
increases with parallel increases in perceived necessity of therapy and decreases in concerns regarding 
the medication.46  The experience of acute hospitalization may increase a patient's perceived disease 
severity, therefore increasing the likelihood of adherence after discharge. Alternatively, it is possible 
that a patient attributes a hospitalization to a lack of effect or adverse consequence of their medication 
leading to decreased adherence after discharge.  
 Evidence based medications for which persistence and treatment duplication were assessed  in 
this study consisted of two classes, LLDs and ACE inhibitors/ARBs. ACE inhibitors and ARBs are 
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used interchangeably in therapy and were regarded as a single class of medications for this study. We 
hypothesized that hospital admission would increase the likelihood that disruption of a patient's 
medication regimen would occur, thus causing unintentional discontinuation of evidence based 
therapies as well as duplications of drug therapy in error. We expected disruption to occur because of 
the many systematic modifications made to the medication regimen during hospitalization, and due to 
absent or  sub-optimal hospital based medication reconciliation practices. We expected that along with 
hospitalization, a longer time to follow up with a primary care provider would be associated with a 
decreased likelihood of persistence due to a longer time until potential resolution of errors introduced 
into the medication regimen. 
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CHAPTER 2 
 
METHODOLOGY 
 
 The study was conducted as a matched retrospective cohort study of patients with diabetes 
enrolled with a commercial insurer. The data for this research were provided by Blue Cross Blue Shield 
of Rhode Island and contained information on enrollment and demographics, as well as pharmacy and 
medical claims. Patients were at least 18 years of age as of July 1, 2008 and continuously enrolled for at 
least 12 months between the period of July 1, 2008 to December 31, 2009. All patients were confirmed 
to have a diagnosis code for diabetes. International classification of diseases ninth edition (ICD-9) 
codes from the 2009 Healthcare Effectiveness Data and Information Set (HEDIS)47 were used to 
identify the presence of any code indicative of diabetes or a diabetes related complication (Appendix A) 
throughout each patient's period of continuous enrollment. In addition, all patients were confirmed to 
have used a medication for the treatment of diabetes, defined as the presence of a claim for any oral or 
injectable hypoglycemic agent during each patient's continuous enrollment period.  Patients were 
identified using unique identification (ID) numbers in the data file; IDs without associated values for 
date of birth, gender, and eligibility were removed from the study population.  
Defining Exposure 
 The primary outcome of interest in this study was the odds of persistence with chronic 
medications between hospitalized and non-hospitalized patients. The exposed group in this study 
consisted of patients hospitalized for at least one night (claims from two consecutive days) and for no 
greater than 30 days. Patients with multiple hospitalizations during the study period were excluded from 
the patient population. Current Procedural Terminology (CPT) codes from the 2009 HEDIS (Appendix 
B)47 were used to identify acute and non-acute inpatient episodes of care representative of an eligible 
hospitalization. Coding for emergency department visits was not included in the definition of an eligible 
hospitalization. Patients with an eligible hospitalization stay were required to have 180 days of 
continuous enrollment prior to the date of admission and 60 days after the date of hospital discharge. 
Medication use was evaluated prior to hospital admission with two medication classes (Appendix C), 
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angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) and lipid 
lowering drugs (LLD). Inclusion into the final cohort of exposed patients required at least two 
prescription claims for one or more medications within one of these classes during the 180 days prior to 
hospitalization. Separate analyses were conducted for each medication class, allowing for patients to be 
included in each analysis group if medications from both classes were used during the baseline period. 
Unexposed Matching 
 Patients without a hospital stay during the study period were unexposed and a source of 
potential matches for eligible exposed patients. Hospitalized patients were initially linked with all 
potential matches that consisted of non-hospitalized patients of the same age and gender. Of these 
potential matches, patients with an enrollment period that encompassed the entire 180 day baseline and 
60 day post hospitalization period of the linked exposed patient were retained. Matched patients were 
assigned an index date identical to the relevant hospitalized patient, with entirely coincident baseline 
and follow up periods. At least two prescription claims for the same study medication class used by the 
hospitalized patient were confirmed for potential matches during the 180 day baseline period. The final 
matching criterion was a comorbidity score calculated using weights as described by Charlson et al and 
updated ICD-9 codes identified by Quan et al.48,49 A comorbidity score was calculated for all patients 
and the distribution of scores was then divided into four groups. Since all patients had previously been 
confirmed to have a diagnosis of diabetes, the comorbidity score was calculated without diabetes 
diagnoses. Diabetes related complications were still included in the score calculation. The majority of 
patients had a minimal comorbid disease burden and the distribution of the comorbidity score was 
highly skewed (Appendix D). Due to the skewed distribution, the four groups were created as follows: 
no comorbid disease (score of 0), one comorbid disease (score of 1), patients with two comorbid 
diseases (score of 2), and three or more comorbid diseases (score of  >3). Potential matches with the 
same comorbidity grouping as the hospitalized patient met all criteria and were eligible to be matched. 
Matches were assigned to hospitalized patients on a one to one basis without replacement. If a 
hospitalized patient had multiple eligible matches, a random number was assigned to all potential 
matches and a final match was assigned at random.  
Defining Persistence 
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 Persistence was previously defined by the ISPOR Workgroup as "the duration of time from 
initiation to discontinuation of therapy".30 In our study all patients were required to have at least two 
claims during the baseline period prior to the index hospitalization, and a third claim during the follow 
up period was indicative of continued use of the medication (persistence). Persistence was evaluated as 
a dichotomous variable during the 60 day period following the discharge date of the hospitalized and 
matched patients. Patients without a prescription claim for any medication during this period were 
excluded from the analysis. Persistence was confirmed if the patient filled a prescription during the 60 
day follow up period for any medication within the study drug class of interest. Patients without a claim 
for such a prescription were classified as non-persistent.  
Defining Therapeutic Duplication 
 Therapeutic duplication was evaluated as a dichotomous variable during the 60 day period 
following the discharge date of the hospitalized and matched patients. Patients without a prescription 
claim during the follow up period were excluded from this analysis. Therapy was considered duplicated 
if claims were identified for greater than one generic medication name within a study drug class (ACE 
inhibitors/ARBs and LLD) during the post discharge period. Changes in dosing were not captured as 
therapeutic duplications. To reduce the potential for misclassifying patients using ACE inhibitors/ARBs 
who were intentionally prescribed multiple medications within the same class, patients confirmed to 
have been on multiple medications within the same class during the baseline period were excluded. To 
reduce the potential for misclassifying patients intentionally prescribed multiple LLD, therapeutic 
duplication was evaluated only for statins. Statins are the most commonly used class of LLD and there 
is no clinical situation in which duplicating statin therapy is considered appropriate.41 
Potential Confounding Variables 
Age: Parametric assessment of the relationship between the continuous variable age and the 
dichotomous variable persistence for patients using ACE inhibitors/ARBs depicted a non-linear 
relationship. Age was coded categorically into three groups for the ACE inhibitor/ARB analysis. Age 
was determined to have a linear relationship with persistence for patients using lipid lowering drugs, 
and was coded as a continuous variable.  
Gender: Analyzed as a dichotomous variable. 
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Comorbidity Score Category: The comorbidity score was constructed based upon ICD-9 coding from 
the 180 day baseline period. This variable was grouped into four categories due to its skewed 
distribution. The comorbidity score grouping was used as a criteria for matching non-hospitalized 
patients to hospitalized patients.  
Days' Supply: Patients in this study that received prescriptions containing a supply of medication for a 
period greater than the duration of follow up (60 days) were at risk for misclassification of persistence. 
Hospitalized patients may have additional medication remaining from a prescription filled prior to 
hospitalization, and non-hospitalized patients may have filled a prescription for a duration greater than 
60 days that is not due for a refill during the follow up period. Duration of prescription supply, in days, 
was evaluated during the 180 day baseline period and included in the analysis as a dichotomous 
variable to control for the potential of misclassification. 
Individual Comorbid Diseases: The presence of comorbid cardiovascular, respiratory, and mental health 
disease was identified during the 180 day baseline period using ICD-9 codes from the HEDIS 2009 
(Appendix D).  The cardiovascular disease variable comprised codes for congestive heart failure, 
coronary artery disease, myocardial infarction, and other forms of ischemic and non-ischemic 
cardiovascular disease. Respiratory disease comprised codes for bronchitis, emphysema, and asthma. 
Mental health disorders included codes for schizophrenia, bipolar disorder, major depression, paranoia, 
psychosis, anxiety, autism, panic disorder, personality disorders, acute stress disorders, impulse control 
disorders, anger/aggression disorders, attention deficit disorder, and attention hyperactivity deficit 
disorder. 
Diabetes Medication Regimen: The outpatient diabetes medication regimen was evaluated during the 
180 day baseline period and considered a surrogate for severity of disease. This variable was classified 
categorically into four groups: no outpatient diabetes medication use, monotherapy (no insulin use), 
polytherapy (no insulin use), and any insulin use.  
Medication regimen complexity:  Regimen complexity was calculated as the number of unique chemical 
entities dispensed in the 180 day timeframe preceding the index hospitalization. This variable was 
determined to have a non-linear relationship with persistence for both medication classes and was coded 
categorically into four groups based upon quartiles of distribution. 
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Time Until Primary Care Physician Visit: The time until follow up with a primary care physician was 
assessed only for hospitalized patients during the 60 day post discharge period and presented as 
frequencies and percentages.  
Statistical Analysis: 
 Statistical Analysis Software Version 9.3 was used to analyze the data. Patient characteristics 
of the final matched cohort were stratified by exposure (hospitalization) status and frequency 
distributions were presented separately for each study medication class in Table 1 (ACE 
inhibitors/ARBs) and Table 1a (LLD). The Pearson Chi square test was used to assess differences 
between groups. Continuous variables were compared using t-tests for independent samples or 
Satterthwaites approximate t-test for variables with unequal variance. The bivariate relationships 
between hospitalization and persistence, and between other potential confounders and persistence, are 
presented in Table 2 (ACE inhibitors/ARBs)  and table 2a (LLD). Frequencies and percentages of 
patients persisting were presented for each characteristic as well as the bivariate odds of persistence. 
Results with a P-value < 0.05 were statistically significant.  
 Risk factor logistic regression modeling was employed to construct two multivariable models, 
one each for the matched cohort of patients using ACE inhibitors/ARBs (Table 3a) and the matched 
cohort of patients using lipid lowering drugs (Table 3b). Hospitalization was the risk factor of interest, 
with all other independent variables considered potential confounders of the relationship with the 
dependent variable of persistence. Assessment for collinearity was conducted with all possible 
confounders for each model. The presence of collinearity was determined based upon identifying a 
large condition index (>20) with multiple variables associated with a proportion of variance > 0.50. To 
evaluate if inclusion of interaction terms improved the model fit, the log likelihood test was used to 
compare models with interaction terms to reduced models. The difference in the –2 log statistic between 
the full model and the reduced model was compared to the corresponding Chi square statistic with the 
degrees of freedom equal to the difference in the number of terms in the models. The full model 
contained all possible two-way interactions, and a backwards elimination process was used to remove 
the least significant interaction terms at each step. Only interaction terms with a p-value < 0.10 were 
retained in the final model.  
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 A confounding assessment was performed for all variables. The hospitalization beta estimate 
for the full model with all variables and retained interaction terms was used as the standard for 
comparison. The effect each variable had on the hospitalization beta estimate was evaluated by 
comparing the full model estimate to the estimate from a reduced model containing all items except for 
the variable being assessed (Appendix E).. Variables that conferred a significant change in the beta 
estimate when eliminated from the model were identified as confounders that were important for 
inclusion in the final multivariable model. The final multivariable model for each drug class contained 
all significant confounders, interaction terms, and other variables deemed clinically important for model 
inclusion. The c statistic and the Hosmer-Lemeshow goodness of fit test assessed the calibration of the 
final model (Appendix F). 
 Therapeutic duplication within each medication class was evaluated and presented as 
frequencies and percentages. The frequencies and percentages of hospitalized patients persisting as a 
function of time to follow up with a primary care provider were presented separately (Table 4 and Table 
4a). Time to follow up with a primary care provider was dichotomized at the median, which was the 
same for both hospitalized ACE inhibitor/ARB users and LLD users. 
 14 
 
CHAPTER 3 
 
RESULTS 
 
 A total of 8,891 patients met all inclusion criteria (Figure1) and were subsequently evaluated 
for selection into the exposed cohort of hospitalized patients (Figure 2). Of these patients, 270 were 
confirmed to have had an eligible hospitalization in conjunction with the use of medication from a study 
drug class prior to admission (207 ACE inhibitors/ARBs and 206 LLD). A total of 7,421 patients 
without a hospitalization were assessed for matching eligibility with patients in the exposed cohort. An 
equal number of unique non-hospitalized patients were assigned as matches for the two cohorts of 
hospitalized patients. After matching was performed, any exposed or unexposed patients without at 
least one prescription claim in the follow up period were excluded prior to analysis. The final cohort of 
patients using ACE inhibitors/ARBs that were evaluated for persistence consisted of 201 exposed and 
199 unexposed individuals.  The final cohort of patients using lipid lowering drugs that were evaluated 
for persistence consisted of 202 exposed and 199 unexposed individuals.   
ACE Inhibitor/ARB Baseline Characteristics 
 The analytic cohort of ACE inhibitor/ARB users was comprised of 400 patients (Table 1). The 
exposed and unexposed patients did not differ on the matched variables of age, gender and comorbidity 
index grouping. The mean (standard deviation [SD]) age of hospitalized patients and non-hospitalized 
patients was 56.84 [7.82] and 56.86 [7.80], respectively. There was no statistically significant difference 
in age between groups for each stratum (P > 0.947 for all 3 stratum). The majority of the cohort was 
male, 66.67% of the hospitalized group of patients and 65.83% of the non-hospitalized group 
(P=0.859). The prevalence of respiratory, cardiovascular and mental health disease was significantly 
different between groups. Patients with respiratory disease made up 13.93% of the hospitalized group 
and 7.04% of the non-hospitalized group (P=0.025). Patients with cardiovascular disease made up 
24.38% of the hospitalized group and 14.57% of the non-hospitalized group (P=0.013). Patients with 
mental health disorders made up 16.92% of the hospitalized group and 8.54% of the non-hospitalized 
group (P=0.012). Variability existed between groups with regards to outpatient diabetes medication 
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regimens used during the baseline period. Of hospitalized patients, 7.46% were using no diabetes 
medication, 24.38% were using monotherapy without insulin, 39.80% were using polytherapy without 
insulin, and 28.36% were using insulin alone or in combination with other medications. Of non-
hospitalized patients, 5.53% were using no diabetes medication (P=0.433), 38.69% were using 
monotherapy without insulin (P=0.002), 35.18% were using polytherapy without insulin (P=0.339), and 
20.60% were using insulin alone or in combination with other medications (P=0.071). Hospitalized 
patients utilized a significantly larger mean number of distinct medications (10.79 [4.81]) compared 
with non-hospitalized patients [(8.66 [4.40]), (P<0.001)]. Finally, 19.10% of unexposed patients had a 
prescription supply of greater than 60 days compared with 10.45% in the exposed group. Non-
hospitalized patients were significantly more likely to have a prescription supply of greater than 60 days 
(P=0.0147).  
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Figure 1 Eligibility Flowchart: Application of Inclusion and Exclusion Criteria 
 21,153 unique patient IDs 
 
N = 21,140  
 
Missing values for DOB, gender, and/or 
eligibility (exclude 13) 
 
Patients not enrolled for 12 consecutive 
months (exclude 1,862) 
 
N = 19,278  
 
Not age 18 before July 1, 2008 
(exclude 172)            
 
N = 19,106  
 
Absence of ICD-9 code for diabetes or 
diabetes related disorder (exclude 4,331)           
 
N = 14,775 
 
ID not present in the prescription claims data 
file (exclude 3,235) 
 
N = 11,540 
 
No prescription claim for a diabetes medication 
(exclude 2,649) 
N = 8,891 
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Figure 2     Exposure Classification Flowchart 
  
 
 
8,891 patients eligible for inclusion 
 
1,470 patients with >1 hospitalization 7,421 patients without a hospitalization 
(Potential matches) 
N = 845 
Patients without an overnight stay 
(exclude 625) 
 
Patients not enrolled with prescription data for 
180 days prior to and 60 days after 
hospitalization (exclude 438) 
N = 407 
N = 270 
Patients without at least 2 claims for 
medications within either study drug class 
during the 180 day baseline (exclude 137) 
Patients with least two claims for ACE 
inhibitors/ARBs during the baseline period 
N = 207 
Patients with least two claims for lipid 
lowering drugs during the baseline period 
N = 206 
Hospitalized patients using ACE 
inhibitor/ARB therapy included for analysis 
N = 201 
Hospitalized patients using lipid lowering 
drug therapy included for analysis 
N = 201 
 
 Patients without a 
prescription claim post 
hospitalization (exclude 5) 
 Patients without a 
prescription claim post 
hospitalization (exclude 6) 
 18 
 
 
Table 1                                     Baseline Characteristics of Hospitalized and  
Non-hospitalized Patients Using ACE inhibitor/ARB Therapy 
Characteristic Hospitalized  
(Exposed) N = 201 
%     (n) 
Non-Hospitalized 
(Unexposed) N = 199 
%     (n) 
P Value 
 
Days' Supply %     (n) %     (n) P Value 
<60 days 89.55 (180) 80.90 (161) 0.0147* 
>60 days 10.45 (21) 19.10 (38) 
 
 
Age, years 
Mean Age [SD]  P Value 
56.84 [7.82] 56.86 [7.80] 0.981 
%     (n) %     (n) P Value 
Age < 59 53.73 (108) 53.77 (107) 0.994 
59 < Age <63 23.88 (48) 24.12 (48) 0.955 
63 < Age 22.39 (45) 22.11 (44) 0.947 
 
Gender %     (n) %     (n) P Value 
Male  66.67 (134) 65.83 (131) 0.859 
Female 33.33 (67) 34.17 (68) 
 
Comorbid Diseases %     (n) %     (n) P Value 
Asthma/COPD 13.93 (28) 7.04 (14) 0.025* 
Cardiovascular 24.38 (49) 14.57 (29) 0.013* 
Mental Health  16.92 (34) 8.54 (17) 0.012* 
 
Diabetes Drug 
Regimen 
%     (n) %     (n) P Value 
No Drug Therapy 7.46  (15) 5.53 (11) 0.433 
Monotherapy 24.38  (49) 38.69 (77)              0.002* 
Polytherapy 39.80 (80) 35.18 (70) 0.339 
Any Insulin Use 28.36 (57) 20.60 (41)       0.071 
 
Regimen Complexity Mean [SD] Number P Value 
10.79 [4.81] 8.66 [4.40] <0.001 
%     (n) %     (n) P Value 
<6 Medications 10.45 (21) 24.12 (48) <0.001* 
6-8 Medications 22.89 (46) 331.7 (66) 0.022* 
9-12 Medications 35.82 (72) 27.64 (55) 0.079 
12< Medications 30.85 (62) 15.08 (30) <0.001* 
 
Comorbidity Indexa %     (n) %     (n) P Value 
No Comorbid 
Diseases 
55.72 (112) 55.28 (110) 0.929 
Comorbidity Score = 1 15.92 (32) 15.58 (31) 0.925 
Comorbidity Score = 2 15.42 (31) 16.08 (32) 0.857 
Comorbidity Score > 3 12.94 (26) 13.07 (26) 0.969 
a Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant. Pearson chi-square test was used for all categorical comparisons and  
the independent  t-test for continuous variables with equal variance or Satterthwaites 
approximate t-test if variance was unequal 
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Lipid Lowering Drug Baseline Characteristics  
 The analytic cohort of lipid lowering drug users was composed of 401 patients (Table 1a). The 
exposed and unexposed patients did not differ on the matched variables of age, gender and comorbidity 
index grouping. The mean (standard deviation [SD]) age of hospitalized patients and non-hospitalized 
patients was 57.16 [7.42] and 57.23 [7.39], respectively (P=0.927). Males made up 66.83% of the 
hospitalized group of patients and 68.34% of the non-hospitalized group (P=0.747). The prevalence of 
respiratory and mental health disease was significantly different between groups. Patients with 
respiratory disease made up 14.85% of the hospitalized group and 7.04% of the non-hospitalized group 
(P=0.012). Patients with mental health disorders made up 17.33% of the hospitalized group and 8.04% 
of the non-hospitalized group (P=0.005). Cardiovascular disease was unbalanced between groups but 
the difference was not statistically significant. Patients with cardiovascular disease made up 26.24% of 
the hospitalized group and 18.59% of the non-hospitalized group (P=0.067).  Significantly more non-
hospitalized patients utilized single drug outpatient diabetes regimens, whereas significantly more 
hospitalized patients utilized regimens involving insulin. Of hospitalized patients, 6.44% were using no 
diabetes medication, 27.23% were using monotherapy without insulin, 36.63% were using polytherapy 
without insulin, and 29.70% were using insulin alone or in combination with other medications. Of non-
hospitalized patients, 6.03% were using no diabetes medication (P=0.867), 38.69% were using 
monotherapy without insulin (P=0.145), 35.18% were using polytherapy without insulin (P=0.991), and 
18.59% were using insulin alone or in combination with other medications (P=0.009). Hospitalized 
patients utilized a significantly larger mean number of distinct medications (10.79 [4.54]) compared 
with non-hospitalized patients [(8.28 [3.73]), (P=0.001)]. Significant differences between groups also 
existed across all four stratum of the regimen complexity variable. Finally, 15.58% of unexposed 
patients had a prescription supply of greater than 60 days compared with 9.90% in the exposed group, 
this difference was not statistically significant (P=0.088). 
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Table 1a                                    Baseline Characteristics of Hospitalized and  
Non-hospitalized Patients Using Lipid Lowering Drug Therapy 
                                
Characteristic Hospitalized Patients 
(Exposed) 
N = 202 
%     (n) 
Non-Hospitalized 
Patients (Unexposed) 
N = 199 
%     (n) 
P Value 
 
Days' Supply %     (n) %     (n) P Value 
<60 days 90.10 (182) 84.42 (168) 0.088 
>60 days 9.90   (20) 15.58 (31) 
 
Age, years Mean Age [SD]  P Value 
57.16 [7.42] 57.23 [7.39] 0.927 
 
Gender %     (n) %     (n) P Value 
Male 66.83   (135) 68.34 (136) 0.747 
Female 33.17   (67) 31.66   (63) 
 
Comorbid Diseasesc %     (n) %     (n) P Value 
Asthma/COPD 14.85   (30) 7.04   (14) 0.012* 
CVD 26.24   (53) 18.59   (37) 0.067 
Mental Health Diagnosis 17.33 (35) 8.04   (16) 0.005* 
 
Diabetes Regimen %     (n) %     (n) P Value 
No Drug Therapy 6.44 (13) 6.03 (12) 0.867 
Monotherapy 27.23 (55) 38.69 (77) 0.0145* 
Polytherapy 36.63 (74) 36.68 (73) 0.991 
Any Insulin Use 29.70 (60) 18.59 (37) 0.009* 
 
Regimen Complexity Mean [SD] Number P Value 
10.79 [4.54] 8.28 [3.73] <0.001 
%     (n) %     (n) P Value 
<6 Medications 6.93 (14) 23.12 (46) <0.001* 
6-8 Medications 25.25 (51) 35.68 (71) 0.023* 
9-12 Medications 38.12 (77) 27.14 (54) 0.019 
12< Medications 29.70 (60) 14.07 (28) <0.001* 
 
Comorbidity Indexa %     (n) %     (n) P Value 
No Comorbid Diseases 52.97   (107) 53.27   (106) 0.953 
Comorbidity Score = 1 11.88   (24) 11.56   (23) 0.920 
Comorbidity Score = 2 17.33   (35) 16.58   (33) 0.843 
Comorbidity Score > 3 17.82   (36) 18.59   (37) 0.841 
a Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant. Pearson chi-square test was used for all categorical comparisons and  the 
independent  t-test for continuous variables with equal variance or Satterthwaites approximate t-
test if variance was unequal 
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Bivariate Odds of Persistence with ACE Inhibitors/ARBs  
 The bivariate relationship between the dependent variable, persistence with ACE 
inhibitors/ARBs and all other variables are presented as odds ratios with 95% confidence intervals (OR 
[95% CI]) (Table 2). Hospitalization, the risk factor of interest, was associated with a decreased 
likelihood of persistence that did not attain statistical significance (0.733 [0.385 - 1.398]). Patients 
receiving a prescription supply of greater than 60 days had a significantly decreased odds of persistence 
with study medication than those with supplies less than 60 days (0.195 [0.098 - 0.392]). The mean 
(mean [standard deviation]) age of patients that persisted (57.02 [7.81]) was greater than those that did 
not (55.38 [7.63]). Increasing odds of persistence was observed within each age stratum, but none were 
significant. Gender was not associated with a change in the likelihood of persistence. Patients with 
comorbid respiratory disease were slightly more likely to persist (1.589 [0.469 - 5.386]), whereas 
patients with a comorbid mental health diagnosis were slightly less likely to persist (0.701 [0.293 - 
1.673]). Comorbid cardiovascular disease was not associated with a change in the likelihood of 
persistence. The odds of persistence relative to patients taking no medication for their diabetes was 
increased in those using single drug therapy (3.091 [0.834 - 11.454]) and in patients using any insulin 
(1.600 [0.458 - 5.585]) but unchanged in those using multiple drug therapy. The mean number of 
distinct medications used during the baseline period was not different between persistent (9.718 
[4.759]) and non-persistent patients (9.833 [4.509]). Similarly, there were no differences in odds of 
persistence between the four stratum of regimen complexity.  Relative to patients with a comorbidity 
score of 0, those with a comorbidity score of 1 (1.539 [0.566 - 4.187]) or 2 (1.957 [0.656 - 5.832)] had a 
non-significantly increased odds of persistence. A comorbidity score of 3 or greater was not associated 
with a change in the likelihood of persistence.  
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Table 2 Risk of Non-persistence with ACE Inhibitor/ARB Therapy Post Hospitalization  
Associated with Patient Demographic and Clinical Characteristics: 
Bivariate Analyses 
Characteristic Persistent  
(N = 358) 
%     (n) 
Non-persistent  
( N = 42) 
%     (n) 
Odds Ratio  
(95% CI) 
Not Hospitalized 90.95 (181) 10.05 (18) Reference 
Hospitalized 88.06 (177) 11.94 (24) 0.733 (0.385 - 1.398) 
 
Days' Supply %     (n) %     (n) Odds Ratio (95% CI) 
<60 days 88.27 (316) 59.52 (25) Reference 
>60 days 11.73 (42) 40.48 (17) 0.195* (0.098 - 0.392) 
 
Age, years Mean Age [SD]  P Value 
57.022 [7.813] 55.381 [7.635] 0.197 
%     (n) %     (n) Odds Ratio (95% CI) 
Age < 59 57.23 (187) 66.67 (28) Reference 
59 < Age <63 24.58 (88) 19.05 (8) 1.647 (0.721 - 3.761) 
63 < Age 23.18 (83) 14.29 (6) 2.071 (0.826 - 5.191) 
 
Gender %     (n) %     (n) Odds Ratio (95% CI) 
Male 66.20 (237) 66.67 (28) Reference 
Female 33.80 (121) 3.33 (14) 1.02 (0.518 - 2.011) 
 
Comorbid Diseasesa %     (n) %     (n) Odds Ratio (95% CI) 
Asthma/COPD 10.89 (39) 7.14 (3) 1.589 (0.469 -  5.386) 
Cardiovascular 19.55 (70) 19.05 (8) 1.033 (0.458 - 2.329) 
Mental Health  12.29 (44) 16.67 (7) 0.701 (0.293 - 1.673) 
 
Diabetes Regimen %     (n) %     (n) Odds Ratio (95% CI) 
No Drug Therapy 6.15 (22) 9.52 (4) Reference 
Monotherapy 33.24 (119) 16.67 (7) 3.091 (0.834 - 11.454) 
Polytherapy 36.03 (129) 50.00 (21) 1.117 (0.350 - 3.566) 
Any Insulin Use 24.58 (88) 23.81 (10) 1.600 (0.458 - 5.585) 
 
Regimen Complexity Mean Number [SD]  P Value 
9.718 [4.759] 9.833 [4.509) 0.881 
%     (n) %     (n) Odds Ratio (95% CI) 
<6 Medications 17.04 (61) 19.05 (8) Reference 
6-8 Medications 28.21 (101) 26.19 (11) 0.830 (0.317 - 2.179) 
9-12 Medications 32.12 (115) 28.57 (12) 0.796 (0.309 - 2.051) 
12< Medications 22.63 (81) 26.19 (11) 1.036 (0.393 - 2.730) 
 
Comorbidity Indexb %     (n) %     (n) Odds Ratio (95% CI) 
CMI Score = 0 54.75 (196) 16.67 (26) Reference 
CMI Score = 1 16.20 (58) 11.90 (5) 1.539 (0.566 - 4.187) 
CMI Score = 2 16.48 (59) 9.52 (4) 1.957 (0.656 - 5.832) 
CMI Score > 3 12.57 (45) 16.67 (7) 0.853 (0.348 - 2.088) 
a Reference is the absence of the comorbidity   
b 
 Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant. Pearson chi-square tests used for categorical variables and  independent  t-
tests for continuous with equal variance or Satterthwaites approximate t-test if unequal variance 
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 Bivariate Odds of Persistence with Lipid Lowering Drugs  
 The bivariate relationship between the dependent variable, persistence with lipid lowering 
drugs, and all other variables are presented as odds ratios with 95% confidence intervals (Table 2a). 
Hospitalization was not associated with any alteration in the likelihood of persistence (0.918 [0.491 -
1.719]). Patients receiving a prescription supply of greater than 60 days had a significantly decreased 
odds of persistence with study medication than those with supplies less than 60 days (0.167 [0.083 - 
0.337]). The mean (mean [standard deviation]) age of patients that persisted (57.20 [7.25]) was 
equivalent to those that did not persist (57.16 [8.58]). Gender was not associated with a change in the 
likelihood of persistence. Patients with comorbid respiratory disease were slightly less likely to persist 
(0.754 [0.299 - 1.901]). Comorbid mental health or cardiovascular disease were not associated with a 
change in the likelihood of persistence. The odds of persistence relative to patients taking no medication 
for their diabetes was increased in those using single drug therapy (2.750 [0.864 - 8.756]), multiple drug 
therapy (1.912 [0.635 - 5.759]) and in patients using any insulin (1.955 [0.610 - 6.258]). The mean 
number of distinct medications used during the baseline period was not different between persistent 
(9.49 [4.40]) and non-persistent patients (9.98 [3.80]). Compared to patients using the fewest number of 
medications (less than 6) during the baseline period, those in each other stratum of regimen complexity 
(6-8, 9-12, 12< medications) were more likely to persist.  Relative to patients with a comorbidity score 
of 0, those with a comorbidity score of 1 or 2  had a comparable likelihood of persistence. A 
comorbidity score of 3 or greater was associated with an increased odds of persistence (1.891 [0.698 - 
5.122]). 
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Table 2a Risk of Non-persistence with Lipid Lowering Drug Therapy Post  
Hospitalization Associated with Patient Demographic and Clinical Characteristics: 
Bivariate Analyses 
Characteristic Persistent  
(N = 357) 
%     (n) 
Non-persistent 
 (N = 44) 
%     (n) 
Odds Ratio  
(95% CI) 
Not Hospitalized 89.45 (178) 10.55 (21) Reference 
Hospitalized 89.05 (179) 10.95 (23) 0.918 (0.491 - 1.719) 
 
Days' Supply %     (n) %     (n) Odds Ratio (95% CI) 
<60 days 90.48 (323) 61.36 (27) Reference 
>60 days 9.52 (34) 38.64 (17) 0.167* (0.083 - 0.337) 
 
Age, years Mean Age [SD]  P Value 
57.20 [7.25] 57.16 [8.58] 0.978 
 
Gender %     (n) %     (n) Odds Ratio (95% CI) 
Male 67.23 (240)  70.45 (31) Reference 
Female 32.77 (117) 29.55 (13) 1.162 (0.586 -2.304) 
 
Comorbid 
Diseasesa 
%     (n) %     (n) Odds Ratioa  (95% CI) 
Asthma/COPD 10.64 (38) 13.64 (6) 0.754 (0.299 - 1.901) 
CVD 22.41 (80) 22.73 (10) 0.982 (0.465 - 2.074) 
Mental Health  12.61 (45) 13.64 (6) 0.913 (0.365 - 2.283) 
 
Diabetes Regimen %     (n) %     (n) Odds Ratio (95% CI) 
No Drug Therapy 5.60 (20) 11.36 (5) Reference 
Monotherapy 33.89 (121) 25.00 (11) 2.750 (0.864 - 8.756) 
Polytherapy 36.41 (130) 38.64 (17) 1.912 (0.635 - 5.759) 
Any Insulin Use 24.09 (86) 25.00 (11) 1.955 (0.610 - 6.258) 
 
Regimen  
Complexity 
Mean Number [SD]  P Value 
9.49 [4.40] 9.98 [3.80] 0.434 
%     (n) %     (n) Odds Ratio (95% CI) 
<6 Medications 15.97 (57) 6.82 (3) Reference 
6-8 Medications 29.97 (107) 34.09 (15) 2.663 (0.740 - 9.582) 
9-12 Medications 32.77 (117) 31.82 (14) 2.273 (0.628 - 8.227) 
12< Medications 21.29 (76) 27.27 (12) 2.999 (0.809 -11.125) 
 
Comorbidity 
Indexb 
%     (n) %     (n) Odds Ratio   (95% CI) 
CMI Score = 0 59.09 (26) 52.38 (187) Reference 
CMI Score = 1 13.64 (6) 11.48 (41) 0.950 (0.367 - 2.456) 
CMI Score = 2 15.91 (7) 17.09 (61) 1.212 (0.501 -2.930) 
CMI Score > 3 11.36 (5) 19.05 (68) 1.891 (0.698 - 5.122) 
aReference is the absence of the comorbidity   
b 
 Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant. Pearson chi-square test was used for all categorical comparisons and  the 
independent  t-test for continuous variables with equal variance or Satterthwaites approximate t-
test if variance was unequal 
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Multivariable Logistic Regression Model: ACE Inhibitor/ARB Cohort 
 The results of a multivariable logistic regression analysis of the effect of hospitalization on 
persistence with ACE inhibitor/ARB therapy, adjusted for relevant confounders and interaction terms, 
are presented in Table 3. Collinearity was not found between any of the independent variables assessed 
for inclusion into this model. A single interaction term between the risk factor (hospitalization) and 
cardiovascular disease met criteria and was included in the final model. After adjusting for all potential 
confounders and the interaction between hospitalization and cardiovascular disease, the beta coefficient 
representing the relationship between hospitalization and persistence was significant (-0.931 
[P=0.0283]). Due to the inclusion of an interaction term in the model, the odds of persistence in 
hospitalized patients relative to non-hospitalized patients are presented separately for individuals with 
and without cardiovascular disease. Patients that were hospitalized and had cardiovascular disease had 
an increased odds of persistence relative to patients that were not hospitalized that had cardiovascular 
disease (2.052 [0.384-10.972)]. Patients that were hospitalized and did not have cardiovascular disease 
were significantly less likely to persist compared with patients that were not hospitalized and did not 
have cardiovascular disease (0.394 [0.171-0.906]). The only other significant term in the final model 
was the duration of prescription supply. Patients receiving a prescription supply of greater than 60 days 
were less likely to have persisted (0.127 [0.056-0.287]) compared with those with a supply of 60 days 
or less.  
 Assessment for confounding involved comparison of the beta coefficient and P-value for 
hospitalization from the final model with the beta coefficient and P-value obtained from a reduced 
model absent the potential confounder of interest. A substantial change upon variable removal was 
indicative of confounding. Duration of prescription supply impacted a large magnitude change in the 
beta coefficient upon removal from the model. Prescription supply was also significantly associated 
with hospitalization, and as a result was identified as a confounder. Through this same process, the 
diabetes regimen and medication regimen complexity variables were also identified as confounders. 
The inclusion of all other variables in the model was determined necessary to adjust for differences in 
baseline characteristics and due to clinical importance. 
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Table 3                  
Influence of Hospitalization on Persistence with ACE Inhibitor/ARB Therapy:  
Results of a Multivariable Logistic Regression Model 
Characteristic Beta 
Coefficient 
Standard 
Error 
Odds Ratio (95% CI) 
Not Hospitalized - - Reference 
Hospitalized -0.931* 0.425 - 
Hospitalized (Cardiovascular disease)a - - 2.052 (0.384 - 10.972) 
Hospitalized (No cardiovascular disease)a - - 0.394* (0.171 - 0.906) 
 
Days' Supply Odds Ratio (95% CI) 
<60 days - - Reference 
>60 days -2.067* 0.418 0.127* (0.056 - 0.287)  
 
Age, years Odds Ratio (95% CI) 
Age < 59 - - Reference 
59 < Age <63 0.580 0.470 1.787 (0.711 - 4.491) 
63 < Age 1.000 0.529 2.719 (0.963 - 7.675) 
 
Gender Odds Ratio (95% CI) 
Male - - Reference 
Female 0.057 0.393 1.058 (0.490 - 2.288) 
 
Comorbid Diseasesb Odds Ratio (95% CI) 
Asthma/COPD 0.570 0.751 1.769 (0.406 - 7.700) 
Cardiovascular -0.936 0.689 - 
Cardiovascular (Non-hospitalized)c - - 0.392 (0.10 - 1.515) 
Cardiovascular (Hospitalized)c - - 2.044 (0.532 - 7.846) 
Mental Health  -0.624 -0.624 0.536 (0.191 - 1.507) 
 
Diabetes Regimen Odds Ratio (95% CI) 
No Drug Therapy - - Reference 
Monotherapy 1.364 0.722 3.912 (0.950 - 16.100) 
Polytherapy 0.0572 0.631 1.059 (0.307 - 3.648) 
Any Insulin Use 0.693 0.705 1.999 (0.502 - 7.957) 
 
Regimen Complexity Odds Ratio (95% CI) 
<6 Medications - - Reference 
6-8 Medications 0.785 0.572 2.193 (0.715 - 6.720) 
9-12 Medications 0.989 0.567 2.689 (0.885 - 8.163) 
12< Medications 1.007 0.642 2.736 (0.777 - 9.637) 
 
Comorbidity Indexd Odds Ratio (95% CI) 
CMI Score = 0 - - Reference 
CMI Score = 1 0.138 0.598 1.148 (0.356 - 3.704) 
CMI Score = 2 0.575 0.591 1.777 (0.558 - 5.661) 
CMI Score > 3 -0.572 0.552 0.564 (0.191 - 1.663) 
a Interaction of hospitalization and cardiovascular disease included in model, odds of persistence for 
hospitalized relative to non-hospitalized patients reported with and without cardiovascular disease 
b Reference is the absence of the comorbidity 
c 
 Odds of persistence for patients with/without cardiovascular disease by hospitalization status 
d
 Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant at < 0.05 
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Multivariable Logistic Regression Model: Lipid Lowering Drug Cohort 
 The results of a multivariable logistic regression analysis of the effect of hospitalization on 
persistence with lipid lowering drug therapy, adjusted for relevant confounders and interaction terms, 
are presented in Table 3a. Collinearity was not found between any of the independent variables assessed 
for inclusion into this model. There were no interaction terms that met criteria for inclusion into the 
final model. The odds of persistence did not differ between hospitalized patients and non-hospitalized 
patients (0.961 [0.469-1.972]). Patients receiving a prescription supply of greater than 60 days were 
much less likely to persist (0.146 [0.068 - 0.313]) relative to patients with a supply of less than or equal 
to 60 days. Patients utilizing medication to treat diabetes had an increased odds of persistence compared 
to patients not on drug therapy, regardless of whether it was monotherapy, polytherapy or any regimen 
containing insulin. The increased odds of persistence achieved statistical significance for patients using 
monotherapy (3.765 [1.064-13.324]). A consistently lower likelihood of persistence was observed in the 
three groups of patients with greater regimen complexity (6-8, 9-12, 12<  medications) relative to those 
using 5 medications or less during the baseline period, but this result did not achieve statistical 
significance.  
 A confounding assessment was carried out using the process described for the ACE 
inhibitor/ARB model. Duration of prescription supply caused a large magnitude change in the beta 
coefficient upon removal from the model. The negative association between prescription supply and 
hospitalization approached significance (P = 0.088), as a result prescription supply was identified as a 
confounder. Through this same process, the diabetes regimen and medication regimen complexity 
variables were both identified as confounders. The inclusion of all other variables in the model was 
determined necessary to adjust for differences in baseline characteristics and due to clinical importance. 
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Table 3a                  
Influence of Hospitalization on Persistence with Lipid Lowering Drug Therapy Adjusted 
for: Prescription Supply Duration, Age, Gender, Comorbid Disease Burden, Diabetes 
Medication Regimen and Number of Medications Used 
Results of a Multivariable Logistic Regression Model 
 
Characteristic Beta Coefficient Standard Error Odds Ratio  
(95% CI) 
Not Hospitalized - - Reference 
Hospitalized -0.040 0.367 0.961 (0.469 - 1.972) 
 
Days' Supply Beta Coefficient Standard Error Odds Ratio (95% CI) 
<60 days - - Reference 
>60 days -1.926* 0.389 0.146* (0.068 - 0.313) 
 
Age, years Beta Coefficient Standard Error Odds Ratio (95% CI) 
Age a 0.006 0.024 1.006 (0.959 - 1.055) 
 
Gender Beta Coefficient Standard Error Odds Ratio (95% CI) 
Male - - Reference 
Female 0.071 0.380 1.074 (0.509 - 2.262) 
 
Comorbid Diseasesb Beta Coefficient Standard Error Odds Ratio (95% CI) 
Asthma/COPD -0.527 0.617 0.591 (0.176 - 1.977) 
Cardiovascular -0.018 0.437 0.982 (0.417 - 2.312) 
Mental Health  0.079 0.535 1.082 (0.379 - 3.086) 
 
Diabetes Regimen Beta Coefficient Standard Error Odds Ratio (95% CI) 
No Drug Therapy - - Reference 
Monotherapy 1.326* 0.645 3.765* (1.064 - 13.324) 
Polytherapy 1.121 0.623 3.068 (0.907 - 10.378) 
Any Insulin Use 1.199 0.678 3.316 (0.878 - 12.520) 
 
Regimen Complexity Beta Coefficient Standard Error Odds Ratio (95% CI) 
<6 Medications - - Reference 
6-8 Medications -1.205 0.694 0.299 (0.077 - 1.167) 
9-12 Medications -1.071 0.712 0.343 (0.085 - 1.382) 
12< Medications -1.279 0.770 0.278 (0.062 - 1.259) 
 
Comorbidity Indexc Beta Coefficient Standard Error Odds Ratio (95% CI) 
CMI Score = 0 - - Reference 
CMI Score = 1 0.417 0.615 1.517 (0.454 - 5.064) 
CMI Score = 2 0.495 0.505 1.640 (0.610 - 4.412) 
CMI Score > 3 0.917 0.601 2.501 (0.770 - 8.129) 
a Age variable coded as continuous 
 bReference is the absence of the comorbidity     
c 
 Charlson comorbidity index48 with updated weighting from Quan et al49 
*  P value is significant 
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Therapeutic Duplication 
 Therapeutic duplication occurred infrequently with both medication classes regardless of 
exposure status. Of the 189 hospitalized patients that were only using a single ACE inhibitor or ARB 
during the baseline period, 3 (1.59%) duplicated therapy during the post-hospitalization period. 
Similarly, of the 186 non-hospitalized patients that were using a single drug during the baseline period, 
1 patient (0.54%) duplicated therapy during the follow-up period. Of the 186 hospitalized patients that 
had 2 or more claims for a statin during the baseline period, 1 patient (0.54%) duplicated therapy. A 
total of 3 (1.63%) non-hospitalized patients duplicated statin therapy of the 184 that had 2 or more 
claims for a statin during the baseline period.  
Time to Primary Care Physician Visit 
 The number of patients persisting was similar between patients with a shorter (<12 days) time 
until a follow up visit with a primary care provider compared with patients with a longer (12< days) 
time until follow up for both ACE inhibitors/ARBS (P=0.537) and for LLDs (P=0.786) (Table 4 and 
Table 4a).   
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Table 4 Influence of Time to Follow Up with a Primary Care 
Provider on Post Discharge Persistence in Hospitalized  
Patients Using ACE Inhibitors/ARBs 
Time Until Follow Upa Persistent 
 N = 97 
%     (n) 
Non-Persistent   
N = 104 
%     (n) 
P Value 
<12 days 47.46 (84) 54.17 (13) 0.537 
12< days 52.54 (93) 45.83 (11) 
 
a
 The median time until follow up with a primary care physician was 12 days; 19 patients did not 
follow up within the 60 day period and were grouped with the patients that had a time until follow 
up of 12< days 
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Table 4a                         Influence of Time to Follow Up with a Primary Care 
Provider on Post Discharge Persistence in Hospitalized  
Patients Using Lipid Lowering Drug Therapy 
Time Until Follow Upa Persistent 
 N = 179 
%     (n) 
Non-Persistent   
N = 23 
%     (n) 
P Value 
<12 days  50.84 (91) 47.83 (11) 0.786 
12< days 49.16 (88) 52.17 (12) 
 
a
 The median time until follow up with a primary care physician was 12 days; 19 patients did not 
follow up within the 60 day period  and were grouped with the patients that had a time until follow 
up of 12< days 
 32 
 
CHAPTER 4 
 
DISCUSSION 
 
 Transitions of care present a particularly vulnerable time for patients. Inadequate 
communication both between providers and with the patient has the potential to introduce inaccuracies 
into the medication regimen and precipitate inappropriate medication taking behavior. Consequent 
adverse drug events are often preventable, and contribute to increased healthcare utilization and 
expenditures. The IOM report "Preventing Medication Errors" emphasized transitions of care as an area 
that requires substantial research to better understand and address the incidence of medication errors.2 
Institutions, clinicians and professional organizations, amongst others, have since mobilized in an effort 
to determine what patient populations are at the greatest risk and what interventions are most effective 
for improving patient safety. 
 The present study investigated the potential of hospitalization to disrupt continuity of 
appropriate medication use by comparing persistence with evidence based chronic medications between 
hospitalized and non-hospitalized patients with diabetes. An increased likelihood of inappropriate 
discontinuation was hypothesized for hospitalized patients using medications within both classes 
studied, ACE inhibitors/ARBs and LLDs. The effect of hospitalization on persistence [Beta estimate (P-
value)] was not consistent between these two medication classes, as hospitalization was a significant 
risk factor for non-persistence with ACE inhibitors/ARBs [-0.931 ( P=0.028)] but there was no effect on 
the odds of persistence with LLDs [-0.036 (P=0.922)]. The significant negative effect of the risk factor 
of interest on the odds of ACE inhibitor/ARB persistence [Odds ratio (95% CI)] was modified by the 
presence [2.052 (0.384-10.972)] or absence [0.394 (0.171-0.906)] of cardiovascular disease. Without 
inclusion of the interaction between hospitalization and cardiovascular disease in the multivariable 
model, hospitalization was no longer a significant risk factor for non-persistence (Appendix F). The 
bivariate models for each medication class supported the lack of association between hospitalization 
and LLD persistence [0.918 (0.491-1.719)] and the mitigated relationship between hospitalization and 
ACE inhibitor/ARB persistence [0.733 (0.385-1.398)].  
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 We also investigated hospitalization as a possible risk factor for inappropriate duplication of 
therapy with both classes of study medications. The low frequencies of duplication observed [(ACE 
inhibitor/ARB:1.59% hospitalized, 0.54% non-hospitalized); (LLD: 0.54% hospitalized, 1.63% non-
hospitalized)] precluded bivariate and multivariable analysis for this outcome. Therapeutic duplication 
was found to be infrequent in this population due to a confluence of factors. To reduce the likelihood of 
misclassification, duplication was only assessed for statins as a subclass of the broader class of LLD. 
The use of multiple LLDs may be therapeutically indicated, whereas the use of more than 1 statin is not 
appropriate in any clinical situation. Similarly, patients that filled multiple ACE inhibitor/ARB 
prescriptions during the baseline 180 days were excluded from the duplication analysis during the 
follow up period. It was not possible to determine if the use of multiple drugs from this class was 
therapeutically appropriate during the baseline period. Other contributors to the observed low frequency 
of duplication may be the ease of detection for healthcare providers and the use of decision support 
software that would flag the prescription prior to dispensing. It is also possible that patients were 
duplicating therapy at home from previously dispensed prescriptions, in which case we would be unable 
to detect such inappropriate medication usage. 
 The duration of prescription supply emerged as a significant confounder of the association 
between hospitalization and persistence. The number of patients that received a prescription supply of 
greater than 60 days for a study medication during the baseline period was unevenly distributed 
between the hospitalized and non-hospitalized groups. In the bivariate and multivariable analyses, a 
supply duration of greater than 60 days increased the odds of non-persistence for ACE inhibitors/ARBs 
and LLDs. This phenomenon may be explained by continued use of a 90 day prescription that was filled 
before hospital admission, or in matched patients, the sustained use of a 90 day prescription that was not 
due for a refill during the follow up period. In either case, patients would be at risk for being 
misclassified as non-persistent despite appropriate use of the study medication. Inclusion of the days' 
supply variable in the final model was essential in order to adjust for the effect of supply duration, 
which if left unadjusted would have obscured the effect of hospitalization on non-persistence. In 
contrast, therapeutic duplication is more likely to have been underestimated as a result of 
misclassification in this study. Patients choosing to continue taking a medication prescribed prior to 
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hospitalization, in addition to another medication within the same class prescribed upon discharge, 
would be inappropriately duplicating therapy. Such duplication is not detectable unless the patient 
refills the original prescription during the follow up period, which may not be necessary if the original 
supply was for greater than 60 days.  
 Evaluations of real-world medication usage by patients apply the terms adherence (synonym: 
compliance) and persistence to describe two separate constructs.30 Other terms have been used to 
describe persistence (discontinuation rates, continuous adherence, persistency, time of continuous 
adherence), and reports have frequently stated that the endpoint under investigation was persistence 
when it was in fact adherence and vice versa. Medication adherence is the act of conforming to the 
recommendations of the provider with respect to timing, dosage, and frequency of medication taking. 
Medication persistence refers to the duration of time from initiation to discontinuation of therapy.30 In 
our study, the outcome of persistence was dichotomized and patients were categorized as persistent or 
non-persistent depending on the presence or absence of a prescription claim indicating therapy 
continuation during a pre-specified period of time. All patients were required to have at least two claims 
during the baseline period prior to the index hospitalization, and a third claim during the follow up 
period was indicative of continued use of the medication (persistence).  
 The healthy adherer effect postulates that improved clinical outcomes in adherers to drug 
therapy compared with non-adherers is not entirely attributable to the benefits of the medication.50 
Instead, adherence to medication is a surrogate marker for overall healthy behavior, which introduces 
bias if left unaccounted for in an analysis of drug effect.51 The effects of healthy adherers are not 
evident in our results, but a separate construct that influences medication taking behavior may be 
implicated.  
 Consistent with our hypothesis, hospitalization disrupted medication use for patients without 
cardiovascular disease. In contrast to our hypothesis, patients with a history of cardiovascular disease 
that were hospitalized were more likely to persist relative to patients with cardiovascular disease that 
were not hospitalized. This latter finding aligns with the tenants of the 'Necessity-Concerns Framework' 
conceptual model for understanding patient's perspectives on prescribed medicines.46 A meta-analysis 
of 94 studies assessed the utility of this model, determining that better adherence to medications for 
 35 
 
chronic disease was associated with stronger perceptions of the necessity of treatment [Pooled OR 
1.742 (95% CI 1.569-1.934)] and fewer concerns about potential adverse effects of treatment [Pooled 
OR 0.504 (95% CI 0.450-0.564)].46 Recently hospitalized patients with diabetes and comorbid 
cardiovascular disease may be more likely to perceive the necessity of treatment with antihypertensive 
medications and overlook concerns about adverse effects, contributing to the results observed in our 
study. 
 Factors associated with medication persistence are dependent upon the characteristics of the 
patient population, the medication class, and the data source being evaluated. A study of persistence by 
Gregoire et al prospectively recruited 692 patients presenting to 173 pharmacies in Ontario, Canada, 
with a new prescription for an antihypertensive medication from 1 of 3 classes including ACE 
inhibitors, ARBs, and calcium channel blockers.52 Data were collected through a structured 
questionnaire during a telephone interview within five days of study entry, and again at 1 month, 3 
months, and a fourth time between 18 and 32 months after enrollment. The results of a multivariate 
hazard model determined that the likelihood of non-persistence was greater in patients that lacked 
insurance coverage (odds of discontinuation in patients with any insurance coverage of 0.74; 95% CI 
0.53-0.97), reported medication side effects (OR 1.91; 95% CI 1.47-2.47), or reported a belief of no 
drug effect (OR 1.29; 95% CI 0.97-1.71). The proportion of patients discontinuing therapy was 11.9% 
at 1 month, 23.8% at 3 months, and 43.3% based upon the last observation for each individual within 
the study period. Of these patients that were no longer on the original therapy, 32.3% had changed to 
another antihypertensive drug and 11% were no longer receiving drug treatment for hypertension. The 
survey based design was advantageous for detecting the influence of patient beliefs about drug effects 
on persistence, but the results of this study are also limited by the accuracy of the surveyed patient's 
responses and the intervals of time between survey administration.52  
 Jackevicius and colleagues assessed primary medication non-adherence to newly prescribed 
medications at discharge from a hospitalization due to acute myocardial infarction (AMI).53 A 
retrospective cohort study was performed utilizing AMI registry data of patients from 104 hospitals in 
Canada. Registry data were linked to prescription claims, vital statistics, physician services, and 
hospital discharge databases. Patients included were at least 66 years of age upon discharge and had an 
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ICD-9 code  for AMI. The primary outcome was death within 1 year after discharge. Primary adherence 
(the risk factor of interest) was categorized as all medications, some medications, or no medications 
filled within 120 days after the discharge date. Discharge prescriptions written for ACE inhibitors were 
not filled within 120 days in 3.82% of patients, while prescriptions for statins were not filled in 5.15% 
of patients within 120 days. Fill rates of non-cardiac medications that were assessed in this study were 
substantially lower than fill rates for cardiac medications (34.6% vs 82.3%; P<0.0001). A significantly 
increased risk of death was observed in patients that failed to fill all (OR 1.80; 95% CI 1.35-2.42) or 
some medications (OR 1.44; 95% CI 1.15-1.79) prescribed at discharge relative to patients that filled all 
prescriptions within 120 days. Receipt of pre-discharge counseling was associated with a reduced 
likelihood of death within 1 year (OR 0.71; 0.58-0.87). In this study prescription data was not available 
from private insurers and as a result only elderly patients were included. Rates of primary non-
adherence following hospitalization for AMI were low, but these results are unlikely to represent 
younger or commercially insured populations.53  
 The findings by Gregoire et al and Jackevicius et al reinforce the proposed connection between 
patient perceptions of medication efficacy and the necessity for compliance and persistence with 
therapy.52-53 In the survey study by Gregoire et al both patient perceived absence of drug effectiveness 
and the occurrence of adverse effects attributed to the drug were associated with significantly lower 
persistence.52 Instead of directly reported perceptions, patients in the study by Jackevicius et al were 
retrospectively selected based upon recent hospitalization specifically for AMI.53 The finding of 
substantially higher primary adherence rates with cardiac medications follows directly from the 
recognition of elevated cardiac risk that would be anticipated in patients following a hospitalization for 
AMI. Insurance coverage, a predictor of persistence identified by Gregoire,52 was not a factor in our 
study since all patients were confirmed to be enrolled with the same commercial insurer. Additional 
covariates that were not associated with changes in persistence including age, gender, and comorbid 
disease burden were evaluated and yielded concordant results with those obtained in our present 
research.52 Identification of patients that received pre-discharge counseling, a predictor of persistence in 
the study by Jackevicius,53 was not possible with our commercial claims data source.  
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 Long term use of evidence based, guideline recommended oral therapies for heart failure has 
been shown to reduce morbidity and mortality.54 The Get With The Guidelines-Heart Failure program is 
an ongoing, prospective, observational data collection and quality improvement initiative that collects 
information on medical history, hospital care and clinical outcomes.55 Krantz et al assessed the inpatient 
patterns of use and continuation of ACE inhibitors/ARBs, aldosterone antagonists, and beta blockers 
while also determining predictors of use.56 Patients included for evaluation had reduced ejection 
fraction (EF<40%) heart failure and were admitted to hospitals participating in the program across the 
United States. In patients with no contraindication to therapy, the proportion of patients using ACE 
inhibitors/ARBs, beta blockers, and aldosterone antagonists at admission was 65.3%, 72.6% and 15.6%, 
respectively. The proportion of patients using ACE inhibitors/ARBs, beta blockers, and aldosterone 
antagonists at discharge was 92.9%, 90.1% and 26.2% respectively. Of the population of patients that 
were already receiving ACE inhibitors/ARBs at hospital admission, 2.6% did not persist with the 
medication at discharge. The strongest predictors of ACE/ARB usage at discharge were medication 
usage at admission (OR 7.4; 95% CI 4.6-11.8), the absence of concomitant renal insufficiency (OR 2.7; 
95% CI 2.1-3.4), and the absence of concomitant hypertension (OR 1.34; 95% CI 1.02-1.77). These 
results are limited by the lack of available persistence data for the period following hospital discharge.56  
 In the study by Krantz et al patients with heart failure that were taking ACE inhibitors/ARBs 
upon admission into the hospital were more than 7 times as likely to be discharged on the medication 
compared with patients admitted that were not receiving a drug from this class.56 Our study design 
included only patients that were confirmed to be using a medication from a study drug class prior to a 
hospital admission. We observed a proportion of patients with cardiovascular disease that did not persist 
with ACE inhibitor/ARB therapy of 10.26%, which was much larger than the 2.6% that did not persist 
in the study by Krantz et al.56 Much of this difference can likely be explained by the definition of 
persistence, which was measured at discharge by Krantz and did not require confirmation of a 
prescription dispensing after the patient left the hospital.56 Although persistence patterns with statins 
were not assessed in this population of heart failure patients, we found a comparable rate of non-
persistence with statins in patients with cardiovascular disease of 10.11%.  
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 Quality of care measures provided prior to hospitalization have been shown to impact 30 day 
re-hospitalization rates in a nationally representative population of commercially insured adult patients 
with diabetes.57 Chen et al evaluated data from the IMS Lifelink Database to determine if receipt of 2 or 
more HbA1c tests, 1 or more LDL tests, at least 90 days of a statin supply dispensed, or at least 90 days 
of an ACE inhibitor/ARB supply dispensed in the year preceding a hospitalization reduced the odds of 
readmission within 30 days of discharge.57 In a multivariate logistic regression model that adjusted for 
patient demographic and comorbid disease characteristics, odds of readmission were significantly 
decreased with the receipt of at least 1 LDL test (OR 0.92; 95% CI 0.85-0.99) or receipt of at least 90 
days of a statin prescription (OR 0.91; 95% CI 0.85-0.97). Odds of readmission were marginally 
decreased with at least 90 days of an ACE inhibitor/ARB prescription (OR 0.94; 95% CI 0.88-1.01) or 
with receipt of at least 2 HbA1c tests (OR 0.94; 95% CI 0.87-1.02). The impact of the performance of 
quality of care measures preceding a hospitalization on readmission rates demonstrated in this study 
was limited by the lack of persistence data following discharge and the absence of a comparator group 
of non-hospitalized patients.57 
 Bell et al recently evaluated the risk of unintentional discontinuation of medications prescribed 
to treat chronic disease in patients undergoing 1 or more transitions of care.6 Similar to the study by 
Jackevicius,53 this study utilized linked prescription claims, vital statistics, physician services, and 
hospitalization databases to identify elderly patients (age > 66) admitted to all acute care hospitals in 
Ontario, Canada.6 Patients were required to be continuous users for at least 1 year of at least 1 
medication from 5 medication classes: statins, antiplatelets/anticoagulants, levothyroxine, respiratory 
inhalers, and gastric acid suppressants. Exposure was categorized into three groups: non-hospitalized 
patients (unexposed), hospitalized patients (1 transition of care), and hospitalized patients that spent 
time in the ICU (2 transitions of care). The primary outcome of interest was the absence of a 
prescription renewal for a drug from within the original medication class in the 90 days following the 
index date (the date of discharge for hospitalized and a randomly assigned date for non-hospitalized 
patients). Compared with non-hospitalized patients the odds of unintentional discontinuation were 
increased in hospitalized patients without an ICU stay [(statins: OR 1.33; 95% CI 1.29-1.37), 
(antiplatelets/anticoagulants: OR 1.86; 95% CI 1.77-1.97), (levothyroxine: OR 1.18; 95% CI 1.14-1.23), 
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(respiratory inhalers: OR 1.50; 95% CI 1.15-1.97), and (gastric acid suppressants: OR 1.50; 95% CI 
1.43-1.56)] and increased further in hospitalized patients with an ICU stay [(statins: OR 1.48; 95% CI 
1.39-1.57), (antiplatelets/anticoagulants: OR 2.31; 95% CI 2.07-2.57), (levothyroxine: OR 1.51; 95% CI 
1.38-1.66), (respiratory inhalers: OR 1.84; 95% CI 1.10-3.08), and (gastric acid suppressants: OR 1.87; 
95% CI 1.71-2.05)]. The composite secondary outcome of death, emergency department visit, or 
emergent hospitalization during a period of 91 days to 365 days post discharge was more likely to occur 
in patients that discontinued statins (OR 1.07; 95% CI 1.03-1.11) or antiplatelets/anticoagulants (OR 
1.10; 95% CI 1.03-1.16) within the 90 days after discharge. These results provide valuable context for 
the relationship between non-persistence and adverse health outcomes in a large representative 
population of elderly adults following a hospitalization. Risk for adverse events following 
discontinuation was not equal between medication classes, with the greatest risk observed in 
medications used for the prevention of macrovascular events.6  
 Improving outcomes following a hospitalization, including reducing 30 day readmission rates, 
has become an incentivized priority with the implementation of the Affordable Care Act.58 
Underperforming hospitals with increased readmission rates for certain disease states relative to other 
similar institutions are subject to reduced reimbursement.58 The results presented by Chen suggest that 
adherence to recommended processes of care for commercially insured patients with diabetes will 
positively influence 30 day readmission rates.57 Bell and colleagues demonstrated that appropriate use 
of chronic medications in elderly patients is disrupted incrementally by 1 or more transitions of care. 
Furthermore, non-persistence following a hospitalization with medications for the prevention of adverse 
macrovascular outcomes (statins, antiplatelets/anticoagulants) placed elderly patients at an increased 
likelihood for 1 year mortality and rehospitalization.6 Our study evaluated a commercially insured 
population, similar to Chen,57 but persistence after a hospitalization was measured with medication 
classes used for the prevention of micro and macrovascular outcomes, similar to Bell.6 Considering 
these relevant findings, our results indicate that patients with diabetes and comorbid cardiovascular 
disease that were not hospitalized, as well as patients hospitalized without cardiovascular disease, may 
also be at an increased risk of adverse health outcomes due to lower rates of persistence. Further studies 
 40 
 
designed to follow persistence patterns and evaluate health outcomes are necessary in patients with 
diabetes.  
  Based upon our multivariable model, certain populations of LLD users are possibly at greater 
risk of unintentional discontinuation of LLD therapy. A non-significant trend was observed for 
decreasing comorbid disease burden associated with increasing odds of non-persistence (Table 3a). 
Similarly, patients without documented use of a medication for diabetes treatment during the baseline 
period were the least likely to persist with LLD therapy. An opposite tendency was demonstrated with 
regards to regimen complexity. In agreement with our hypothesis, patients using the least number of 
medications during the baseline period had the greatest relative likelihood of persisting. These 
conflicting phenomena are presumed to be the consequence of multiple contributing factors and random 
variation. Healthier patients with diabetes that were not using hypoglycemic medication and had a 
minimal burden of comorbid disease may not have perceived LLD treatment as necessary and were 
consequently at an increased risk for non-persistence. In addition to polypharmacy, the regimen 
complexity variable may have captured a separate indicator of disease burden that was not fully 
reflected in the comorbidity score grouping and was associated with an increased risk for non-
persistence. Ultimately the main result of the LLD multivariable analysis was that after adjusting for all 
possible confounders, there was no difference in odds of persistence between non-hospitalized and 
hospitalized patients with diabetes (0.961 [0.469 - 1.972]).  
 Studies evaluating relative rates of mortality and other adverse health outcomes between 
adherent/persistent patients with non-adherent/non-persistent patients have demonstrated that 
appropriate usage of statins and ACE inhibitors/ARBs is associated with better clinical outcomes.6-7, 33-
38
 This result should be expected when these drugs are used for evidence based indications in patient 
populations for which expert professional organizations have published guidelines recommending their 
use.40-41, 54 A more difficult question involves the determination of what level of patient adherence is 
necessary to achieve the beneficial effects of the medication before a difference in clinical outcomes is 
manifested. This uncertainty applies indirectly to persistence. When the definition of persistence is 
established for a study protocol, it is necessary to identify what period of time must elapse between the 
dispensing of two prescriptions that is indicative of non-persistence. A longer permissible gap will 
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directly translate into a lower acceptable level of adherence that is necessary to remain persistent. In our 
present study, a period of 60 days without a prescription claim for the medication was used. Assuming a 
30 day prescription supply (87.31% of the LLD cohort, 85.04% of the ACE inhibitor/ARB cohort), if 
the patient filled a prescription immediately prior to the beginning of the 60 day follow-up period then 
an adherence level of 50% would be sufficient to last the 60 days without another prescription fill. An 
adherence level greater than 50% would result in a refill during this period confirming persistence, but 
the proportion of therapeutic effect achieved by a persistent patient with reduced adherence remains 
uncertain.  
 Rasmussen et al addressed the problem of relative risk for incremental levels of adherence in a 
population of elderly adults (age >66) in Ontario, Canada, following a hospitalization for AMI.33 For 
inclusion into the study, all patients were required to fill a prescription for either a statin, beta-blocker, 
or calcium channel blocker in the 3 months after hospital discharge. In the year following dispensing of 
the first study medication, the proportion of days covered (PDC) was determined and levels of 
adherence were subdivided into 3 categories (high adherence: PDC > 80%; intermediate adherence: 
PDC > 40%-79%; and low adherence: PDC > 40%). The primary outcome of long term mortality was 
assessed over a median period of 2.4 years. Non-persistence was determined over the full period of 
follow up and defined as the absence of an expected prescription based upon previous quantities 
supplied, evaluated over 6 month periods from each previous prescription dispensing. Non-persistence 
at the end of follow up was 13.2%, 19.6% and 33.5% for statins, beta blockers, and calcium channel 
blockers, respectively. A dose-response type relationship was observed with the risk of mortality (HR; 
95% CI) increasing with decreasing levels of adherence with statins [(intermediate adherence: 1.12; 
1.01-1.25), (low adherence 1.25; 1.09-1.42)] and beta blockers [(intermediate adherence: 1.01; 0.93-
1.09), (low adherence 1.13; 1.03-1.25)]. This relationship was stronger with statins than with beta 
blockers, and was not detected with calcium channel blockers. The absence of an adherence-mortality 
relationship for calcium channel blockers, a medication class which does not have any proven post-AMI 
survival advantages, supports the attribution of a survival benefit for the other medication classes to 
drug effect rather than the healthy adherer effect. 33 
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 Recognition of the detrimental outcomes occurring secondary to inappropriate management of 
the medication regimen during care transitions has lead to the development and evaluation of numerous 
institution specific interventions.15-16 Due to the fragmented nature of the United States health system 
and the logistical difficulties in organizing large multi-site trials, stakeholders have typically 
approached the issue individually as it directly relates to a specific practice population, professional 
discipline, or institution. Individualized programs targeting care transitions have involved a multitude of 
different healthcare providers including nurses,17-19 physicians,20 pharmacists,17-19,21-23 pharmacy 
technicians,24,28 and nurse practitioners.25-26 Examples of interventions include medication reconciliation 
at admission and or discharge, post discharge phone calls or home visits, motivational coaching and 
education, or a combination of multiple interventions.17-28  These interventions have yielded varying 
degrees of success on clinical and surrogate outcomes, with limited generalization to larger populations. 
 Care transition interventions are often compared with the standard of care provided prior to 
implementation of the intervention at the institution.20, 23-25 A systematic review of the literature by 
Kripalani et al sought to characterize the types and prevalence of deficits in communication between 
hospital based and community based physicians at hospital discharge.20 A total of 55 observational 
studies that had been published from 1970 through 2005 were included. In these studies, 3% of primary 
care physicians reported being involved in discussions about discharge and 17-20% reported always 
being notified of discharges. Within 1 week of discharge, a median of 53% (30-94%) of discharge 
letters and 14.5% (9-20%) of physician dictated discharge summaries had reached the primary care 
physician. In addition, 11% of discharge letters and 25% of discharge summaries never reached the 
primary care physician. Interventional studies included in the review involved either provision of 
computer generated and manually created discharge summaries, changes in the mode of information 
delivery, or reformatting of the discharge documents. No standardized measures were used across 
studies, and results indicated a mix of significant and non-significant improvements in timeliness of 
discharge communication. This systematic review of the literature emphasizes the historical 
inefficiencies of hospital physician to outpatient physician communication and the limited application 
of institution specific interventions for broader health system improvement.20  
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 Pharmacist intervention during care transitions has demonstrated varying levels of success. 17-
19,21-23 A randomized controlled trial that assessed pharmacist counseling at discharge was carried out at 
a single academic hospital in Boston, Massachusetts.18 Routine care involved the review of medication 
orders by the ward based pharmacist and discharge counseling provided by a nurse, which sometimes 
consisted of informal medication reconciliation. The multifaceted pharmacist intervention consisted of 
evaluation for previous drug related problems (side effects, non-adherence), reconciliation of discharge 
medications with admission medications, and the review of discharge medications with the patient. A 
follow-up phone call 3 to 5 days after discharge was also performed by the pharmacist. During the 
phone call, medication use by the patient was reconciled with discharge medication instructions and 
adherence to post hospital care was assessed and communicated to the outpatient primary care 
physician. A significant reduction in preventable ADE's (1% intervention vs 11% usual care; P=0.01) 
was observed at 30 days post discharge. The total number of ADEs and resource utilization was similar 
between groups, but the number of preventable medication related emergency department visits and 
readmissions was reduced in the intervention group (1% vs 8%; P=0.03). Pharmacists are capable of 
performing medication reconciliation, and were shown to beneficially impact post discharge medication 
use. The small number of patients participating in the trial and the short period of follow up may have 
limited the ability to demonstrate an overall reduction in ADEs and resource utilization.18 
 Another randomized controlled study conducted at an academic hospital in Boston, 
Massachusetts, achieved improvements in post discharge hospital utilization with coordinated discharge 
intervention by a nurse and pharmacist.19 A nurse discharge advocate arranged follow up appointments, 
reconciled medications with outpatient records, and conducted inpatient education. The pharmacist 
performed follow-up phone calls in the week post discharge to perform a medication review and 
subsequent corrective action as needed. Compared to usual care, the 30 day combined re-hospitalization 
and emergency department visit rate was reduced (incident rate ratio: 0.695; 95% CI 0.515-0.937). The 
proportion of patients following up with their primary care provider after discharge was significantly 
greater in the intervention group (62% vs 44%; P=0.007). The nurse discharge advocate spent an 
average of 87.5 minutes, and the pharmacist an average of 26 minutes, per patient providing 
intervention related services. A cost analysis considering the cost of follow up appointments and 
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hospitalization determined that an estimated $412 per person was averted in the intervention group 
compared with usual care. This estimation was limited since it did not account for the cost of the 
intervention, although it was determined that the intervention could be partially implemented using the 
present hospital employee structure. The authors concluded that in a traditional fee for service model, 
the additional services provided by the intervention would not be incentivized through reimbursement 
and would be less likely to be implemented than in a capitated or pay-for-performance model.19 
 Other studies have been unable to demonstrate a clear benefit of pharmacist intervention 
during care transitions.21, 23 One randomized controlled study investigated the effect of an integrated 
pharmacy discharge plan involving hospital and community pharmacists from 4 hospitals and 29 
community pharmacies.23 The intervention involved hospital pharmacist development of medication 
and supportive discharge plans for provision to all necessary healthcare providers, as well as a home 
follow up visit by a community pharmacist after discharge.  The comparison group received usual care, 
consisting of a discharge letter to the PCP and no pharmacist pre-discharge medication review. No 
significant difference was found with regards to the primary outcome of 6 month readmission between 
the control (28.4%) and intervention groups (27.9%).  Secondary endpoints measured included 
adherence, comprehension, mortality, and healthcare usage. Similar results on the secondary outcomes 
were reported for both groups.23 
 A care transition intervention implemented by Coleman et al utilized strategic patient and 
caregiver education.25 The objective of the patient focused intervention was to prepare for future self-
management of the medication regimen during care transitions and provider interactions. Community 
dwelling elderly adults (age > 65) were recruited upon admission to the study hospital located in 
Colorado. A total of 158 patients were included in the intervention and matched to administrative 
controls derived from a managed care delivery system with an existing contract with the study hospital. 
Patients and their caregivers that received the intervention were provided with tools and support in 
order to actively participate in the transition from hospital to home. A geriatric nurse practitioner served 
as a transition coach, contacting the patient via telephone and visiting for home visits. The transition 
coach performed medication reconciliation during the home visit, and assisted in preparing the patient 
for handling future interactions with care providers. The median duration of the intervention for an 
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individual patient was 24 days. The primary outcome was the odds of rehospitalization, which was 
significantly reduced in the intervention group at 30 days (OR 0.52; 95% CI 0.28-0.96), 90 days (OR 
0.43; 95% CI 0.25-0.72) and 180 days (OR 0.76; 95% CI 0.36-0.92) after hospital discharge. The 
results of this study are limited by the quasi-experimental design but suggest that an initial investment 
in patient education by a specialized transition coach is successful in reducing future resource 
utilization. A cost effectiveness evaluation of a similar intervention, evaluated prospectively in a larger 
population, would help inform further development of coaching based care transition interventions.25 
 Inconsistent results have been reported from a multitude of institution or region specific 
studies that have evaluated interventions targeting transitions of care.15-26 The importance of 
standardization is implicit in the High 5s project presently being implemented internationally by 
participant countries within the World Health Organization.27-29 The demonstrable implementation and 
evaluation of standardized operating procedures (SOPs) across different cultural, geographic, and 
medical care settings involved in this project has been proposed as preferable to the traditional medical 
approach of individualized best practice.29 Early results of the SOP for medication reconciliation have 
been positive, demonstrating reduced incidence of medication errors upon admission for elderly 
patients.27-28 Use of a standardized procedure has contributed to distinct obstacles during 
implementation of the SOP.29 Hospitals utilizing pharmacy technicians to obtain a complete medication 
history have outperformed hospitals with physician or nursing based models.28 This differential 
outcome from the same underlying process draws attention to potential difficulties encountered with a 
standardized approach. Expertise is not entirely coincident between practice disciplines and allocation 
of responsibility to specific healthcare practitioners will be inconsistent between institutions. The 
success of the SOP for medication reconciliation, if sufficiently validated, will still require cross-
disciplinary collaboration and tailoring of the SOP to best function within individual practice sites.  
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CHAPTER 5 
 
LIMITATIONS AND CONCLUSION 
 
The present study utilized a retrospective matched cohort design to ensure that hospitalized 
and non-hospitalized patients were similar with regards to age, gender, comorbidity burden and 
enrollment period. The purpose of matching in this study was to ensure that the group of non-
hospitalized patients was similar to the group of hospitalized patients. Despite the matching procedure, 
a significantly higher percentage of hospitalized patients had diagnoses indicating respiratory and 
cardiovascular disease, and mental health disorders. While our multivariate analyses attempted to 
control for these differences, it is possible that the effect of hospitalization on medication persistence 
was biased by the greater overall disease burden among the hospitalized group. Due to the retrospective, 
non-randomized study design and the use of claims data it was not possible to adjust for all possible 
confounders. As a result, the potential for uncontrolled residual confounding existed due to additional 
variables that may have included but were not limited to socioeconomic status, healthcare service 
utilization, delivery of medication counseling, education level achieved, and patient perceptions 
regarding benefits and detriments of pharmacy care services. An additional limitation was the breaking 
of matches after the matching procedure had been completed that caused minor inequalities between the 
size of hospitalized and  non-hospitalized patient populations in both study drug cohorts. This resulted 
from exclusion of patients that did not have a prescription claim during the follow up period. This 
procedure was necessary to prevent misclassification of patients no longer filling prescriptions with the 
insurer as non-persistent, but it may have further contributed to the unequal distribution of confounders 
between groups. 
 The primary outcome of interest, persistence, is a surrogate marker for adverse health 
outcomes that are expected to follow the inappropriate discontinuation of evidence based therapies for 
chronic disease. A comparison of readmission and/or mortality rates between persistent and non-
persistent patients would be useful to fully characterize the adverse effects of medication disruption by 
inpatient hospitalization. Moreover, the potential for misclassification surrounding the primary outcome 
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must be considered. Although the medication classes selected for this study are recommended for use in 
broad populations of patients with diabetes,39 it is possible that the medications were intentionally 
stopped by prescribers for legitimate reasons. Such causes may have included intolerable adverse 
effects, newly developed contraindications to therapy, or lifestyle control of the medical condition that 
precluded the necessity for continued drug treatment. Detection of prescription fills for persistence 
confirmation was also limited to claims submitted to the commercial insurer. Prescriptions that were 
bought without insurance or with alternative insurance coverage would not be detected and patients 
would be at risk for misclassification. We sought to mitigate such bias through the exclusion of patients 
that did not have a prescription claim for any medication during the follow up period. Our exclusion of 
such patients contributed to an underestimation of persistence if it is presumed that these patients filled 
their prescription without reimbursement from Blue Cross Blue Shield of Rhode Island. With claims 
data, adherence to prescription medications is determined using the surrogate marker of a prescription 
dispensing. It is possible that patients picked up medication but then did not proceed to take it, resulting 
in misclassification of baseline adherence or follow up persistence. 
 Our study is believed to be the first to evaluate persistence patterns following hospitalization in 
a commercially insured population with diabetes that was adherent to evidence based therapy prior to 
hospitalization.  The use of a matched comparator group of patients with diabetes that were not 
hospitalized sought to preclude the introduction of bias and improved the interpretability of our results. 
The capacity for generalization of our results is limited to a commercially insured population with 
diabetes using ACE inhibitors/ARBS or LLDs. Further research evaluating persistence and successive 
clinical outcomes in this population is required to better characterize the impact of regimen disruption 
secondary to hospitalization. Confirmation of our results is also warranted in nationally representative 
populations of elderly and commercially insured patients with diabetes. Future studies using outpatient 
claims data would be improved through an integrated analysis with inpatient and outpatient medical 
records, which would increase the specificity for identifying true non-persistence. Intentional 
medication discontinuation would be detectable in the medical chart, comorbid disease burden would be 
verifiable, and information on additional potential confounders would be available for assessment. 
Ideally, medical records and claims data will be used together to evaluate the effect of a care transition 
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intervention, such as medication reconciliation, in a randomized prospective study conducted across 
multiple institutions. Such a large scale and rigorous study methodology is necessary to generate widely 
applicable evidence of improved clinical outcomes and to justify funding and implementation of 
specific care transition interventions. 
 In conclusion, hospitalization was found to be a significant risk factor for ACE inhibitor/ARB 
discontinuation in commercially insured patients with diabetes without comorbid cardiovascular 
disease. Hospitalized patients with cardiovascular disease were more likely to persist with ACE 
inhibitor/ARB therapy than non-hospitalized patients with cardiovascular disease. Hospitalization was 
not found to disrupt continuation of LLD treatment after discharge, as persistence rates were similar to 
non-hospitalized patients. A prescription supply of greater than the number of days in the follow up 
period was identified as a strong confounder of persistence with both drug classes. Prescription supply 
duration should be considered in future studies measuring persistence. Further evaluation of the 
disruptive impact of hospitalization on appropriate medication use in patients with diabetes should 
focus on quantifying increased risk of adverse health outcomes with non-persistence and the 
effectiveness of care transition interventions on preventing unintentional medication discontinuation.
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APPENDIX A 
 
 
 
ICD-9 CODES TO IDENTIFY DIABETES 
 
25000  25001  25002  25003  25010  25011  25012  25013  25020  25021  25022  25023 25030  25031  
25032  25033  25040  25041  25042  25043  25050  25051  25052  25053  25060  25061  25062  25063  
25070  25071  25072  25073  25080  25081  25082  25083  25090  25091  25092  25093  3572    36201  
36202  36203  36204  36205  36206  36207  36641  64801  64802  64803  64804 
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APPENDIX B 
 
 
 
HEDIS 2009 CPT CODES TO IDENTIFY VISIT TYPE 
 
Nonacute Inpatient CPT Codes 
 
99301  99302  99303  99304  99305  99306  99307  99308  99309  99310  99311  99312  99313 99315  
99316  99318  99321  99322  99323  99324  99325  99326  99327  99328  99331  99332 99333  99334  
99335  99336  99337 
 
Acute Inpatient CPT Codes 
 
99221  99222  99223  99231  99232  99233  99238  99239  99251  99252  99253  99254    99255 99261  
99262 99263 99291 
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APPENDIX C 
 
 
 
MEDICATIONS WITHIN EACH STUDY MEDICATION CLASS 
 
Ace Inhibitors and Angiotensin Receptor 
Blockers (ARB) 
Lipid Lowering Drugs (LLD) 
Aliskiren  
Aliskiren/Hydrochlorothiazide  
Benazepril Hydrochloride 
Benazepril Hydrochloride/Hydrochlorothiazide 
Candesartan Cilexetil 
Candesartan Cilexetil/Hydrochlorothiazide Captopril 
Captopril/Hydrochlorothiazide 
Enalapril Maleate 
Enalapril Maleate/Hydrochlorothiazide 
Eprosartan Mesylate 
Fosinopril Sodium 
Fosinopril Sodium/Hydrochlorothiazide 
Hydrochlorothiazide/Irbesartan 
Hydrochlorothiazide/Lisinopril 
Hydrochlorothiazide/Moexipril Hydrochloride 
Hydrochlorothiazide/Losartan Potassium 
Hydrochlorothiazide/Olmesartan Medoxomil 
Hydrochlorothiazide/Quinapril Hydrochloride 
Hydrochlorothiazide/Telmisartan 
Hydrochlorothiazide/Valsartan 
Irbesartan 
Lisinopril 
Losartan Potassium 
Losartan Potassium 
Moexipril Hydrochloride 
Olmesartan Medoxomil 
Perindopril Erbumine 
Quinapril Hydrochloride 
Ramipril 
Telmisartan 
Trandolapril 
Trandolapril/Verapamil 
Valsartan 
 
Atorvastatin Calcium 
Amlodipine Besylate/Atorvastatin Calcium 
Cholestyramine 
Colesevelam Hydrochloride 
Colestipol Hydrochloride 
Colestipol Hydrochloride, Micronized 
Ezetimibe 
Ezetimibe/Simvastatin 
Fenofibrate 
Fenofibrate, Micronized 
Fenofibric Acid 
Fluvastatin Sodium 
Gemfibrozil 
Lovastatin 
Lovastatin/Niacin 
Niacin 
Niacin/Simvastatin 
Omega-3-Acid Ethyl Esters 
Pravastatin Sodium 
Rosuvastatin Calcium 
Simvastatin 
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APPENDIX D 
 
 
 
COMORBIDITY SCORE DISTRIBUTION BY MEDICATION CLASS 
(Patients that were eligible for matching and were matched) 
 
Comorbidity Score ACE/ARB 
(N=207 each group)a 
%   (N) 
LLD 
(N=206 each group)b 
% (N) 
0 55.56 (115)   53.40 (110) 
1 15.94 (33) 11.65 (24) 
2 15.46 (32) 16.99 (35) 
3 6.28 (13) 8.74 (18) 
4 2.90 (6) 3.40 (7) 
5 0.48 (1) 0.49 (1) 
6 0.97 (2) 1.94 (4) 
7 0.97 (2) 1.46 (3) 
8 0.97 (2) 0.49 (1) 
9 0 (0) 0.97 (2) 
10 0.48 (1) 0.49 (1) 
a 207 hospitalized and non-hospitalized patients each (total 414) 
b 206 hospitalized and non-hospitalized patients each (total 412) 
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APPENDIX E 
 
 
 
CONFOUNDER ASSESSMENT 
 
ACE Inhibitor/ARB Cohort 
 
Multivariable Logistic 
Regression Model 
 
Parameter Estimate 
(β) 
 
P-value 
Full Modela -0.931 0.028 
Full Model - Age -0.911 0.030 
Full Model - Gender 0.931 0.028 
Full Model - Comorbidity Score 
Group 
-0.929 0.028 
Full Model - Respiratory 
Disease 
-0.915 0.031 
Full Model - Mental Health 
Disease 
-0.936 0.027 
Full Model - Days' Supply -0.662 0.092 
Full Model - Regimen 
Complexity 
-0.811 0.047 
Full Model - Diabetes Severity -1.011 0.016 
a The full model was the standard for comparison and consisted of all potential confounders and the 
two-way interaction between hospitalization and cardiovascular disease 
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APPENDIX E 
 
 
 
CONFOUNDER ASSESSMENT 
 
Lipid Lowering Drugs 
 
Multivariable Logistic 
Regression Model 
 
Parameter Estimate 
(β) 
 
P-value 
Full Modela -0.040 0.914 
Full Model - Age -0.037 0.920 
Full Model - Gender -0.040 0.914 
Full Model - Comorbidity Score 
Group 
-0.122 0.735 
Full Model - Cardiovascular 
Disease 
-0.040 0.913 
Full Model - Respiratory 
Disease 
-0.074 0.839 
Full Model - Mental Health 
Disease 
-0.036 0.922 
Full Model - Days' Supply 0.197 0.572 
Full Model - Regimen 
Complexity 
-0.181 0.607 
Full Model - Diabetes Severity -0.107 0.765 
a The full model was the standard for comparison and consisted of all potential confounders  
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APPENDIX F 
 
 
 
Calibration Assessment of the Final Multivariable Logistic Regression Model  
 
 
Model Hosmer and Lemeshow 
Goodness of Fit 
C Statistic 
 
Final ACE inhibitor/ARB Modela 0.23 0.77 
Final LLD Modelb 0.87 0.73 
a The final model consisted of all potential confounders and the two-way interaction between hospitalization 
and cardiovascular disease 
b The final model consisted of all potential confounders 
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